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ABSTRACT  
Maternal and neonatal infections are a major public health problem leading to high morbidity 
and mortality in middle and low-income countries.  There is a need for effective interventions 
suitable for these countries to reduce the high burden of disease. 
Intrapartum azithromycin is a potential intervention to reduce maternal and neonatal 
infections and their associated deaths.  PregnAnZI-1, the first intrapartum oral azithromycin 
trial was a Phase III, double-blind, placebo controlled randomized clinical trial in which 829 
women in labour were randomized to receive either a single dose of 2g of oral azithromycin 
or placebo (ratio 1:1).  The trial was conceived as a pilot study to determine the impact of the 
intervention on maternal and neonatal bacterial colonization, as a necessary step towards 
sepsis.  Nasopharyngeal swabs (NPS), breast milk (BM) and vaginal swabs (VS) were collected 
from study women and /or their babies during the first 4 weeks of follow-up (day 0, day 3, 
day 6, day 8, day 14 and day 28).  Additionally, NPS were also collected from study children in 
a survey conducted 12 months following the trial.  During the trial follow up period (birth to 
day 28), prevalence of carriage of S. aureus, S. pneumoniae and group B Streptococci 
decreased significantly in the intervention arm, whilst prevalence of azithromycin resistant S. 
aureus increased among mothers or their babies exposed to azithromycin compared to the 
placebo group. 
The aims of my PhD investigations are to determine the long-term impact of such intervention 
on S. aureus colonisation and antimicrobial resistance; molecular epidemiology of 
azithromycin resistant S. aureus and the prevalence of nasopharyngeal macrolide resistance 
genes following intrapartum oral azithromycin intervention. 
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In the survey conducted 12 months following the main trial, a total of 461 NPS were screened 
for prevalence of carriage and azithromycin resistance for S. aureus and S. pneumoniae.  As 
expected there was no difference in the prevalence of nasopharyngeal carriage of S. 
pneumoniae or S. aureus between children whose mothers had been exposed to azithromycin 
during labour and those whose mothers had not (85.0% vs 82.1%; odds ratio [OR], 1.23 [95% 
confidence interval, .73-2.08] for S. pneumoniae and 21.7% vs 21.3%; OR, 1.02 [95% CI, .64-
1.64] for S. aureus).  Also, prevalence of azithromycin-resistant S. pneumoniae (1.8% vs 0.9% 
p= 0.384) and S. aureus (3.1% vs 2.6% p= 0.724) were not different between children from 
the azithromycin and placebo arms, respectively.  The intervention did not induce antibiotic 
resistance to other antibiotics commonly used in Africa for these two bacteria.  
A random selection of 7 mothers and 10 babies from both arms of the trial, who carried S. 
aureus resistant to azithromycin in the nasopharynx at day 3 and day 28 post-intervention 
were included in the second investigation undertaken as part of this PhD.  A total of 66 S. 
aureus isolates underwent genomic investigation.  Seven S. aureus sequence types (STs) were 
identified.  ST5 predominated in the placebo arm (73.0% versus 49.0%, p = 0.039) and ST15 
in the azithromycin arm (27.0% versus 6.0%, p = 0.022). Among azithromycin-resistant 
isolates, msr(A) gene was the main macrolide resistance gene (n = 36, 80%) and was found to 
be located on a multidrug resistant (MDR) plasmid. The intervention appeared to select for 
the ermC gene as 36% of resistant S. aureus isolates from mothers and babies exposed to 
antibiotic carried the gene as oppose to 0% in the placebo arm (p< 0.001). 
Having established that the genetic determinants for S. aureus macrolide resistance were 
predominantly msr(A) and ermC, I assessed the effect of intrapartum oral azithromycin on 
these genes in my final PhD investigation as they were found to be located on mobile genetic 
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elements that can transfer horizontally between bacteria.  PCRs were performed on 936 NPS 
from 312 children at three different time points (birth, day 28 and 12 months).  At birth, 
prevalence of msr(A) gene was similar in both arms, higher in the azithromycin arm by day 28 
(60.7% vs. 29.9% in the azithromycin and placebo arms, respectively; OR, 3.61 [95% CI, 2.20-
5.93]) and again similar between arms at 12 months. Prevalence of ermC followed a similar 
pattern, with differences between arms only apparent at day 28 (63.9% vs. 45.9% in the 
azithromycin and placebo arms, respectively; OR, 2.09 [95% CI, 1.29-3.37]). 
In conclusion, the effectiveness of intrapartum oral azithromycin prophylaxis in decreasing 
carriage of bacteria associated with both maternal and neonatal infections had been 
established. Emergence of azithromycin resistant S. aureus shortly (28 days) following oral 
azithromycin exposure was of concern. However, in the long term (12 months), neither the 
increased azithromycin resistant S. aureus nor the increased nasopharyngeal macrolide 
resistance genes observed shortly following the intervention persisted among mothers or 
their new-borns.  Hence, supporting the use of intrapartum oral azithromycin prophylaxis as 
a means to reduce maternal and neonatal infections in The Gambia and potentially other 
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CHAPTER 1 
1.0 LITERATURE REVIEW 
1.1 Epidemiology of Staphylococcus aureus disease 
S. aureus is a major human pathogen with the ability to infect a range of tissues of the human 
body.  Infections caused by S. aureus can be divided into three general categories: (a) life-
threatening systemic conditions such as; sepsis, bacteraemia, meningitis, osteomyelitis, 
endocarditis, toxic shock syndrome; (b) Skin and soft tissue infections (SSTIs) e.g. impetigo, 
boils, cellulitis, folliculitis, carbuncles, scalded skin syndrome, abscesses and; (c) toxinoses e.g. 
food poisoning [1]. 
Among the range of infections caused by S. aureus, bacteraemia is often more associated with 
higher morbidity and mortality.  In the last 20 years, due to increased frequency of invasive 
procedures, increased numbers of immunocompromised patients, and increased resistance 
of S. aureus strains to available antibiotics, incidence of S. aureus bacteraemia and its 
complications has increased sharply [2-4].  Globally, S aureus bacteraemia is one of the most 
common bloodstream infection [5, 6] and the burden varies between developed [7-9] and 
developing [10-12] countries with developing countries bearing the highest burden. 
 
 1.2 Burden of S. aureus bacteraemia in developed countries  
S. aureus disease ranks very high in the public-health agenda of developed countries as a 
result of high burden of disease associated with the bacteria.  In the United States, S. aureus 
is the most frequently occurring bacterial pathogen among clinical isolates (blood, samples 
from lower respiratory tract, skin and soft tissue) from hospital inpatients and the second 
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most prevalent bacterial pathogen among clinical isolates from outpatients [13].  Annually, 
490,000 hospitalizations; 93,000 cases of bacteraemia; and 35,000 cases of sepsis and/or 
endocarditis are due to S. aureus [14, 15].  In Denmark, among all age groups, incidence of S. 
aureus bacteraemia between 1995 and 2008 was reported to be 22.7 cases per 100,00 person 
years.  The figure increased to about 30 cases among adults aged more than 21 years and 
then increased further to 494 cases among HIV infected individuals age ≥ 16 year [16-18].  
Incidence rates in Iceland, Finland, Sweden and Netherlands are fairly similar ranging 
between 14 to 33 cases per 100,000 person years [19-22]. 
 
1.3 Burden of S. aureus bacteraemia in Sub Saharan Africa  
In developing countries such as those in the Sub Saharan Africa, S. aureus disease does not 
appear to rank very high in the public-health agenda even though these countries bear the 
greatest burden of diseases due to the bacteria [23]. 
Bloodstream infections are among the leading causes of morbidity and mortality in people of 
all ages in sub-Saharan Africa [24].  In Senegal, high rate of S. aureus bacteraemia was 
reported among patients between January 1996 and December 2002 in a hospital in the 
capital Dakar with even high rate of Methicillin-resistant Staphylococcus aureus (MRSA) 
bacteraemia among nosocomial bacteraemia [25].  Among older children age <15 years in 
Mozambique, incidence of S. aureus bacteraemia was reported to be 48 cases per 100,000 
per years [26].  In Kenya, incidence of S. aureus bacteraemia per 100,000 person years among 
children age less than 5 years between 1998 and 2002 was reported to be 27 cases[27].  
Among the same age group, a higher incidence of 630 cases per 100,000 person years of S. 
aureus bacteraemia was reported among Ghanaian children between 2007 and 2009 [28].  It 
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appears at least from the above data that incidence of S. aureus bacteraemia varies 
extensively between countries in Africa with highest incidence in western Africa compared to 
eastern, western and southern African countries.  Similarly, among neonates, S. aureus 
bacteraemia was highest in western Africa accounting for more than 77% of all Gram-positive 
causes of bacteraemia or sepsis compared to 59% in central Africa, 54% in eastern Africa and 
37% in Southern Africa [29]. 
 
1.4 Burden of S. aureus bacteraemia in The Gambia  
 In the Gambia, S. aureus is the main cause of bacteraemia in all age groups and the most 
prevalent cause of neonatal sepsis [11, 30, 31].  More than 15 years ago, S. aureus was the 
second most common cause of bacteraemia among all ages groups accounting for about 
18.3% of bacteraemia cases with a positive blood culture [30].  Incidence among children age 
less than 5 years was more than double to that reported in Kenya but far less than the 638 
cases per 100, 000 reported in Ghana [28].  Prior to introduction of pneumococcal conjugate 
vaccine into the Gambian immunisation program in August 2009, Streptococcus pneumoniae 
was the leading cause of invasive bacterial disease leading to bacteraemia [30].  However, 
following the introduction of the pneumococcal conjugate vaccine, S. aureus became the 
leading cause of invasive bacterial diseases leading to high morbidity and mortality [24].  
Among all age groups, the proportion of S. aureus bacteraemia increased post vaccination 
from 16.9% to 27.2%; becoming the most prevalent bacteria associated with invasive 
bacterial infections in The Gambia [24] Figure 1. 
 
 








Figure 1 Annual trends in major bacterial pathogens associated with invasive bacterial 
infections in The Gambia, 2005–2015, in relation to the introduction of pneumococcal 
conjugate vaccines adapted from [24].  Prevalence of S. aureus bacteraemia (blue line) 





Pre vaccination Post vaccination 
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Incidence of S. aureus bacteraemia among children < 5 years of age in 2 regions in the eastern 
part of The Gambia during 2008–2015 was reported to be 78 cases per 100,000 person-years. 
Among neonates, the number of cases increased substantially to 2,080 cases per 100,000 
person-years [11].  In the eastern region of The Gambia, there exist a health and demographic 
surveillance system that covers a population of about 170,000 in 219 settlements.  Studies 
conducted in these areas report incidence using the total population as the denominator 
whereas in the western regions, only laboratory based data are available. 
 
1.5 Staphylococcus aureus carriage  
Asymptomatic carriage of S. aureus often precedes disease and carriage S. aureus species are 
responsible for transmission in the community and also represent circulating strains in the 
community [32-34].  The carriage of S. aureus varies depending on a number of factors 
including geographic location, age, gender, ethnicity and body niche [35].  The most frequent 
site colonised in adult population includes the nares, throat and perineum.  Other sites such 
as the skin, vagina and intestine are also frequently colonised [35, 36].  Figure 2 shows the 
various body parts colonised by S. aureus  [37].  Colonization offers a reservoir from where 
the pathogen can access the bloodstream for example when breaches appear in host defence 
systems but infections can also occur without nasal colonization [38].  The association of nasal 
carriage and S. aureus disease has been reported as early as 1931 [39].  Subsequently, a 
number of other studies also confirmed the association of S. aureus nasal carriage and disease 
[40-42].  The above findings were supported by the fact that the nasal S. aureus strain and 
the infecting strain share the same phage type or genotype [42]. Furthermore, decolonisation 
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of the nose by applying anti staphylococcal drug have also been shown to temporarily prevent 
S. aureus infection [43]. 
Carriage has been reported to be higher in young children [32], men [44], hospitalised 
patients and a number of other patient groups, including patients with diabetes mellitus [45], 
those with S. aureus skin infection [46], and HIV‐infected patients [37].  In some individuals, 
carriage strains may remain resident for an extensive long period even for a few years [47] 
but it is not clear how nasal carriage is established and maintained [37].  In sub Saharan Africa, 
nasal carriage of S. aureus varies extensively.  In Ethiopia, prevalence of S. aureus nasal 
carriage among pre-School children was reported to be 13% [48].  Among Tanzanian children 
under the age of 5 years, nasal carriage of S. aureus was reported to be 40% [49] and 22.1% 
of Ghanaian children < 15 years of age on admission were reported to carry S. aureus in the 









Figure 2. The various body parts colonised by S. aureus.  Colonisation rates per body site 
increased among nasal carriers reproduced from [37]. 
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1.6 S. aureus carriage in The Gambia  
In The Gambia, a number of studies described carriage of S. aureus from various body sites in 
different age groups [51-53].  In a cohort of Gambian women sampled at delivery and other 
time points during the follow up period, up to 71% of the women were found to carry S. 
aureus at some point in either the nasopharynx, breast milk or vaginal [54].  At least at one 
time point, nasopharyngeal, breast milk and vaginal tract carriage of S. aureus were found to 
be 51.5%, 35.2% and 24.5% respectively [54].  Among older children age 5-10 years 
nasopharyngeal carriage was reported to be up to 25.9% [55].  Nasopharyngeal carriage 
among children age 1 year or less immunised with the pneumococcal conjugate vaccine (PCV-
7) reported 65% and 33.6% oropharyngeal and nasopharyngeal carriage respectively [53].  
Among new-borns sampled during the neonatal period (0-28 days), S. aureus nasopharyngeal 
carriage ranged between 50-63% [52, 56].  Neonatal nasopharyngeal carriage of S. aureus was 
found to be significantly associated with maternal carriage in the breast milk, vaginal tract 
and nasopharynx [54]. 
 
1.7 Transmission  
S. aureus appears to successfully colonise almost all parts of the human body and rates of 
colonisation increased for each site among nasal carriers [37].  As a result of the ubiquitous 
nature of S. aureus carriage, various modes of transmission occur both within the community, 
between mother and child as well as in hospital wards. 
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1.8 Community transmission 
In this mode of transmission, S. aureus is often transferred from the nose to the hand of a 
person, then to a surface, before being transferred via the hand to the nose of a second 
person [57].  Community transmission could also occur through direct skin contact between 
carriers and non-carriers sharing personal hygiene items, for example, razors, towels, or soaps 
[58].  Further, inhalation of air droplets from nasal carriers after sneezing could also result in 
the transfer of the bacterium especially among individuals suffering from viral infections [59, 
60]. 
 
1.9 Mother to child transmission  
S. aureus could also be transmitted from mother to child during the process of the baby 
passage through the birth canal as a result of the baby coming in contact with mother’s body 
fluids [61].  Following delivery, and during breast feeding S. aureus may also transfer from 
mother to baby either from contaminated items or through breast milk [54, 62].  Human milk 
is a continuous source of bacteria for the infant gut, and both culture-dependent and 
microbiome studies have revealed that staphylococci, mainly CNS, constitute the dominant 
bacteria in this biological fluid [63].  Microbial communities in human milk collected from 
mothers living in 11 international sites including The Gambia, revealed 
Streptococcus and Staphylococcus as the core genera in milk although there exist differences 
within and across populations [64]. Studies also indicated that some bacteria present in the 
maternal gut, including staphylococci, can reach the mammary gland during late pregnancy 
and lactation through a mechanism involving gut monocytes [65, 66].  Although S. aureus and 
other bacteria have been detected from breastmilk in mothers participating in the PregnAnZI 
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trial [56] mother to child transmission could have occurred from the skin of the mothers 
breast or through exposure to S. aureus carried by the mothers at other anatomical sites.  In 
light of the above, samples were collected with caution by cleaning the breast areola and 
discarding the initial milk. However, there is always the possibility that some of the bacteria 
was from skin although a good number of bacteria detected from the milk were not typical 
flora. 
  
1.10 Hospital transmission  
In hospital settings, S. aureus is mainly spread from person to person particularly from health 
care workers’ hands if they are not washed or cleansed between contact with different 
patients.  Like in the community, contaminated surfaces in the hospital or medical equipment 
are equally likely to be a platform of transmission of the bacteria [67, 68]. 
 
1.11 Characteristics of Staphylococcus aureus  
1.11.1 S. aureus morphology   
S. aureus is a Gram-positive, non-motile, non-spore forming bacterium that grows rapidly 
under aerobic conditions but can also grow without the need for oxygen (facultative 
anaerobes)[7]. Under the light microscope, S. aureus appears round in shape and forms 
irregular grape-like clusters.  On blood agar, the bacteria appear as glistening, smooth, 
entirely raised translucent colonies that often have a golden pigment Figure 3. 
 




Figure 3 The colony morphology of S. aureus growing on different blood agar plates 
reproduced from [69].  The colonies are 2-3mm in diameter after 24h incubation and most 
strains show β-haemolysis surrounding the colonies. 
 
S. aureus is easily identified by its ability to produce coagulase and hence clot human plasma.  
There are currently 2 subspecies of S. aureus; these are S. aureus subspecies aureus and S. 
aureus subspecies anaerobius [70].  Only the subspecies aureus is commonly isolated from 
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1.11.2 Cellular components 
The components of S. aureus cell are an outer capsule, a thick peptidoglycan layer, 
cytoplasmic membrane, surface proteins and secretary proteins Figure 4. 
 
 
Figure 4. The structure of S. aureus cell reproduced from [7] A shows the surface and 
secreted proteins expressed during the exponential and stationary growth phases. B and C 
shows cross-sections of the cell envelope revealing detail structures of the peptidoglycan 
and capsule. 
 
Like all Gram-positive bacteria, the cell wall of S. aureus is predominantly made of 
peptidoglycan.  Peptidoglycan consists of alternating polysaccharide subunits of N-
acetylglucosamine and N-acetylmuramic acid with 1,4-β linkages [7].  Peptidoglycans are 
known to have endotoxin-like activity that stimulate the release of cytokines by macrophages, 
activate complement system and aggregate platelets [71, 72].  The capacity of S. aureus to 
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cause certain disease conditions such as disseminated intravascular coagulation is strongly 
associated with the differences in the peptidoglycan structure of staphylococcal strains [73].  
S. aureus as well as other staphylococci produce capsule.  These microcapsules are mainly 
made of polysaccharides that are antiphagocytic [74].  So far, up to 11 different serotypes 
have been described however, types 5 and 8 account for 75 percent of human infections [75]. 
 
1.11.3 Surface proteins  
During the exponential growth phase of S. aureus, a number of surface proteins are produced 
including protein A, coagulase, clumping factor, collagen, fibronectin and elastin binding 
proteins Figure 4.  Protein A has antiphagocytic properties that are based on its ability to bind 
to the Fc portion of immunoglobulin [76].  The remaining surface proteins are believed to play 
important roles in immune evasion and during colonisation of the host as they bind to 
extracellular matrix molecules and have been designated microbial surface component 
recognising adhesive matrix molecules (MSCRAMM) [77]. 
 
1.11.4 Secretory proteins  
A number of toxins produced during the stationary phase of S. aureus growth cycle are 
grouped on the basis of their mechanism of action.  These toxins include enterotoxin B, toxic 
shock syndrome toxin-1 (TSST-1) and α toxin.  Staphylococcal enterotoxin B is associated with 
food poisoning, non-menstrual toxic shock, atopic dermatitis, asthma, and nasal polyps in 
humans [78].  Only a few bacteria including S. aureus are known to produce superantigens 
(SAgs).  SAgs are a family of potent immunostimulatory exotoxins.  In S. aureus strains more 
than 20 distinct SAgs have been characterized and 80% of clinical strains harbour at least one 
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SAg gene [79]. The mode of action of SAgs involves activation of T cells leading to 
overproduction of cytokines resulting in systemic inflammation and shock [80].  Classically, 
SAgs are associated with food poisoning and toxic shock syndrome (TSS), for which toxins are 
the causative agent [79].  The α toxin on the other hand causes pore formation and induces 
proinflammatory changes in mammalian cells.  These changes result in cell damage that may 
contribute to manifestations of the sepsis syndrome [81].  S aureus also produces enzymes 
such as protease, lipase and hyaluronidase that destroy tissue and facilitate the spread of 
infection to adjoining tissues.  Other enzymes include β lactamase and coagulase that 
inactivates penicillin and convert fibrinogen to fibrin respectively [82]. 
 
1.11.5 Genome of S. aureus  
The genome of S. aureus consists of a single circular chromosome of about 2.7 – 2.8 mbp.  In 
addition, it has plasmids, mobile genetic elements [insertion sequences (IS) and transposon 
(Tn)], prophages and other variable elements.  Genes governing virulence and resistance to 
antibiotics are found on the chromosome, as well as the extrachromosomal elements [83].  
Location of a gene determines to a large extent whether it could be transmitted vertically or 
horizontally between bacteria.  Virulence or antibiotic resistance genes located on the 
chromosome can transfer from parent to daughter cell following replication.  Additionally, 
recombination involving the exchange of genetic material either between multiple 
chromosomes or between different regions of the same chromosome have also been 
detected in S. aureus genome [84].  Gene transfer can also take place independent of cell 
replication involving extrachromosomal genes.  Key among extrachromosomal genes are the 
plasmids.  Plasmids are small, circular molecules of DNA that are capable of replicating 
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independently.  S. aureus strains carry at least one or more plasmids ranging in size from 1 to 
60kb.  The plasmids are classified into three main classes based on size and ability to 
conjugate. 
Class I consist of small plasmids (1-5kb) occurring between 10 to 55 copies per cell [85].  The 
plasmids are either cryptic or carry a single or in rare instances two resistance determinants.  
Four families made up class I namely pT181, pC194, pSN2 and pE194.  The pT181 family 
contain plasmids conferring chloramphenicol, tetracycline and streptomycin resistance.  
pC194 family contains plasmids conferring resistance to chloramphenicol, aminoglycosides, 
quaternary ammonium compounds and cadmium. Both pSN2 and pE194 plasmid family 
confers resistance to macrolide, lincosamides and streptogramin B [83].  Class II plasmids (15-
30kb) are relatively larger in size compared to class 1 and exist between 4 to 6 copies in a cell.  
The resistance genes are often associated with transposons that have integrated into the 
plasmid genome. They are mainly associated with resistance to penicillin, aminoglycosides or 
trimethoprim resistance [86].  Class III plasmids (30-60k) consists of even larger plasmids and 
carry a number of different resistance determinants for aminoglycosides, trimethoprim, 
quaternary ammonium compounds and some beta lactams [87]. 
In addition to plasmids providing a relatively efficient means for staphylococci to exchange 
genetic information such as antibiotic resistance genes and virulence determinants, a 
comprehensive knowledge of plasmid content is also critical for a full understanding of 
pathogen diversity [88].  Complete genomic analysis of plasmids in strains of S. aureus clone 
USA300 revealed high level of identity among recent isolates but relatively divergent from 
earlier USA300 isolates that comprise the epidemic clone.  The plasmid diversity is probably 
due to varied selective pressures imparted to the parent strain through acquisition of plasmid-
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mediated antibiotic resistance which is common in health care-associated isolates than in 
those from the community [89]. 
 
1.11.6 S. aureus sequence types  
The unambiguous characterization of bacterial isolates in a standardized, reproducible, and 
portable manner was first proposed in 1998 using multilocus sequence typing (MLST) 
approach [90].  MLST has been successfully used to differentiate and trace S. aureus species 
that cause outbreaks or epidemics of infectious diseases.  In the process, the sequences of 
internal fragments of several housekeeping genes are determined for each isolate, thereby 
defining specific alleles for each locus.  In S. aureus, seven housekeeping genes (loci) (arcC, 
aroE, glpF, gmk, pta, tpi, and yqiL) provides a unique allelic profile known as sequence types 
(STs) [91] Figure 5.  As there are many alleles at each of the seven loci, isolates are highly 
unlikely to have identical allelic profiles by chance, and isolates with the same allelic profile 
can be assigned as members of the same clone [92, 93].  So far, more than 6000 S. aureus STs 








Figure 5 Scheme for multilocus sequence typing reproduced from 
https://www.researchgate.net/profile/Werner_Ruppitsch/publication/313256513/figure/fig
6/AS:457794219450371@1486158055299/Scheme-for-multilocus-sequence-typing-
adapted-from-mlstnet-MLST-uses-sequence_W640.jpg.  The scheme uses sequence 
variations in up to seven housekeeping genes.  Allele numbers are assigned to unique 
sequences and the allele number combination result in a ST. 
 
Groups of STs in which every ST shares at least five of seven identical alleles with at least one 
other ST in the group are referred to as clonal complexes [94].  The following clonal 
complexes: CC1, CC5, CC8, CC15, CC22, CC30, CC45, CC97 and CC93 are most frequently seen 
in the MLST database.  They can be assigned unambiguously, with only minimal overlap with 
other complexes. 
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Among 26 European countries between September 2006 and February 2007, 2,890 S. aureus 
isolates were collected from patients with invasive S. aureus infection.  The six most common 
methicillin sensitive S. aureus (MSSA) and methicillin resistant S. aureus (MSRA) were STs 5, 
15, 45, 7, 30, 1 and STs 22, 8, 111, 5, 228, 5 respectively [95].  In the USA, MLST was 
determined for S. aureus bacteraemia cases in 5 academic medical centres between 2008 and 
2011.  The 3 most common MSSA STs were ST5, ST8, and ST30 whilst ST8 and ST5 accounted 
for 83% of the MRSA isolates [96].  In Africa, the six most common MSSA and MSRA sequence 
types were reported to be ST5, ST8, ST15, ST30, ST121 , ST125 and ST5, ST8, ST80, ST88, 
ST239/241 respectively [12].  S. aureus STs appear to vary from one country to another.  
Among children aged less than 15 years in the Ashanti region of Ghana, the dominant 
sequence type was reported to be ST152 followed by ST15 and then ST45 [50].  The STs rarely 
carry the mecA gene therefore rates of MRSA were low.  However, prevalence of Panton-
Valentine leucocidin (PVL) is high hence the STs has the potential to cause severe invasive 
infections [50] as PVL is a virulence factor that targets white blood cells causing leukocyte 
destruction and tissue necrosis [97].  A similar prevalence of sequence types was also 
observed among Ghanaian healthcare institutions [98] suggesting that the carriage STs were 
responsible for infections.  In Kenya, the dominant S. aureus sequence types from selected 
isolates from private and public referral hospitals were ST1, ST8 and ST241 [99].  These STs 
were mostly MRSA and also resistant to a number of antibiotics including clindamycin, 
erythromycin and trimethoprim/sulfamethoxazole.  S. aureus isolated from academic centres 
in South Africa revealed ST612 as the dominant ST [100] whereas clonal complex 5 (CC5) was 
the most dominant among patients in the surgical ward in Nigerian university hospital [101].  
In both countries, the dominant ST were methicillin resistant with the South African ST mainly 
hospital acquired. 
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In The Gambia, there is limited data on the prevalence of S. aureus sequence types.  Ebruke 
C. et al. [102] reported 59 different sequence types of S. aureus isolated from nasopharyngeal 
samples from all age groups of which the dominant sequence types were ST15(28%) and 
ST5(4%).  Like in carriage, the dominant S. aureus sequence types from clinical isolates were 
ST15 and ST5 [103]. 
 
1.11.7 Antibiotic treatment options for S. aureus infections in The Gambia 
The Gambia national standard treatment guideline is the recommended guide for all clinical 
staff in the treatment of S. aureus infection in the Gambia.  However, there is no strict 
monitoring for adherence by The Gambia medical and dental council or the ministry of health.  
Whilst some follow the national guidelines, others use the World Health Organisation 
guidelines and the rest especially those in the rural areas of the country are forced to treat 
suspected S. aureus infections with the available antibiotics.  Overwhelmingly, in hospital 
settings where microbiology laboratory exists, laboratory confirmed S. aureus infection is 
treated with cloxacillin as the first line [11].  The second line treatment options include 
Amoxiclav or Augmentin and macrolides such as azithromycin.  The last line of treatment is 
vancomycin which is rarely available to the clinical staff. 
Data on the antibiotic susceptibility pattern for S. aureus isolates from invasive diseases and 
skin and soft tissue infections (SSTIs) for the cloxacillin, amoxiclav, macrolides or vancomycin 
are limited.  Between 2003 and 2005, 871 patients admitted to Medical Research Council, The 
Gambia ward suspected for bacteraemia had blood culture taken and 18.3% of the samples 
were positive for S. aureus.  All isolates were susceptible to cloxacillin, gentamicin and 
chloramphenicol; moderately susceptible to co-trimoxazole (66.7%) and poorly susceptible to 
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tetracycline (33%) and penicillin (8%) [30].  In a recent publication, 293 S. aureus isolates from 
a cross sectional study based on data compiled from records and samples for patients seen 
at The MRCG clinic during the period January 2005—December 2015 were screened for 
antibiotic susceptibility.  Prevalence of antimicrobial resistance was low and included 
chloramphenicol (4.8%), cefoxitin (2.4%), ciprofloxacin (3.8%), erythromycin (8.9%), 
gentamicin (5.5%) penicillin (92.5%), tetracycline (41.0%), and sulfamethoxazole-
trimethoprim (24.2%) [104]. 
 
1.11.8 S. aureus macrolide resistance genes  
Three main mechanisms of S. aureus macrolide resistance encoded by genes have been 
described.  Firstly, through target-site modification by methylation or mutation that prevents 
the binding of the antibiotic to its ribosomal target.  Secondly, through efflux of the antibiotic, 




Figure 6. The 3 main mechanisms of macrolide resistance coded for my by the erm, msr and 
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In the first mechanism, an adenine nucleotide at position 2058 in the 23S rRNA subunit which 
plays a key role in the binding of macrolides and other antibiotics such as lincosamides and 
streptogramin B may be methylated by an enzyme encoded by erythromycin ribosome 
methylase (erm) gene.  This methylation results in the impairing of the binding of macrolides, 
lincosamides and streptogramin B (MLSB) antibiotics to its target leading to resistance.  In 
pathogenic bacteria, nearly 40 erm genes have been reported [107] and are mostly borne by 
plasmids and transposons.  These erm genes have now been grouped based on their amino 
acid sequence similarity into 21 classes; 4 of which are present in pathogenic bacteria.  The 
four major classes are: erm(A), erm(B), erm(C), and erm(F) [108].  The erm(A) and erm(C) 
genes are typically found in staphylococci [105].  Expression of macrolides lincosamides and 
streptogramin B(MLSB) resistance can be either constitutive or inducible.  In inducible 
resistance, the bacteria produce inactive mRNA that is unable to encode methylase.  The 
mRNA becomes active only in the presence of a macrolide inducer such as 14 or 15 membered 
lactone ring macrolides.  By contrast, in constitutive expression, active methylase mRNA is 
produced in the absence of an inducer [105]. 
The second mechanism of macrolide resistance in staphylococci is through the expression of 
efflux pumps.  These pumps are ABC transporters encoded by plasmid borne genes called 
macrolide and streptogramin resistance genes msr(A/B).  Unlike chromosomal encoded 
pumps in Gram-negative bacteria that contribute to intrinsic resistance to hydrophobic 
compounds [109], these efflux pumps are specific to macrolides and streptogramin B 
antibiotics [110]. 
Finally, resistance could be due to inactivation of the macrolide by two enzymes namely 
phosphotransferases and esterases encoded by mphC and ereA/B genes respectively.  
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phosphotransferases inactivates macrolides by phosphorylating a hydroxyl group on the 
macrolide whereas esterases hydrolysis the lactone ring [109]. 
There are currently very few data in The Gambia on the prevalence of genes associated with 
macrolide resistance following azithromycin interventions. A single study described 
prevalence of antibiotic resistance determinants following mass drug administration of 
azithromycin from 23 S. aureus isolates by phenotype.  The results showed that no macrolide 
resistant determinants were found in six isolates that were sensitive to both azithromycin and 
clindamycin. Five isolates displaying resistance to azithromycin but sensitivity to clindamycin 
were positive for the msr gene, which conveys resistance to macrolides and streptogramin B. 
Twelve isolates were azithromycin resistant and had the iMLSB phenotype and all of these 
carried erm genes confirming their resistance to the MLSB antibiotics [111]. 
 
1.11.9 Transmission of S. aureus macrolide resistant genes  
S. aureus macrolide resistant genes are predominantly located on plasmids that are easily 
transmissible.  S. aureus like many bacteria has the ability to integrate genetic material coming 
from more or less evolutionarily distant organisms.  This mechanism is called “horizontal gene 
transfer” as opposed to vertical transmission from mother to daughter cell [112]. Three 
mechanisms have been described namely transformation, conjugation and transduction 








Figure 7. The three mechanisms of horizontal gene transfer between bacteria reproduced 
from [112] namely transformation, conjugation and transduction. 
 
Transformation simply refers to bacteria taken up free DNA from dead organisms into the 
cytoplasm.  Conjugation on the other hand refers to transfer of genetic material to another 
through direct contact via sexual pilus whilst transduction is a type of transfer that occurs via 
a bacteriophage that transmits the DNA from one cell to another [113]. 
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Transfer of macrolide resistant gene between bacteria colonising an individual could result in 
the emergence of phenotypically resistant bacteria strains that may eventually spread in 
within the population.  These bacteria may be resistant to a number of antibiotics making 
them very difficult to treat. 
 
1.12. Other Staphylococci species  
 
1.12.1 General characteristics  
The genus staphylococcus includes at least 50 different species [114].  Majority of these 
Staphylococci species are harmless and reside normally on the skin and mucous membranes 
of humans and other organisms [115].  They may also be isolated from food products where 
they may be involved in fermentation or from other animals.  Staphylococcus spp. have also 
been reported to cause a wide variety of diseases in humans.   S. saprophyticus, S. epidermidis, 
S. lugdunensis, and S. schleiferi have been implicated in a number of human infections [115-
117].  In addition, some coagulase-negative staphylococci (CoNS) have also emerged as 
important pathogens in hospital-acquired infections [115].  They are particularly associated 
with the use of indwelling or implanted foreign bodies and often transmit from one patient 
to another through medical and or nursing procedures [118]. 
 
1.12.2 Staphylococci and macrolide resistance genes 
Staphylococci species other than S. aureus are also known to carry genes associated with 
macrolide resistance. The msrA gene that codes for an efflux pumps which actively pumps 
25 | P a g e  
 
macrolides and streptogramins out of the bacterial cell was first identified in Staphylococcus 
epidermidis [110].  There are currently no data on the prevalence of macrolide resistance 
genes among other Staphylococcal species in the Gambia.  However, in Turkey, prevalence of 
macrolide resistant genes among erythromycin-resistant clinical isolates of coagulase-
negative staphylococci was reported to be 30% for ermC and 32% for msr(A) [119].  In a study 
conducted in Germany among erythromycin resistant coagulase negative staphylococci, most 
(63%) erythromycin-resistant isolates carried constitutively expressed ermC as the sole 
resistance determinant and the msr(A) gene was carried by 20–30% of all erythromycin-
resistant isolates [120].  Macrolide resistance genes were also described among S. 
saprophyticus in France [121],  Staphylococcus species in Argentina [122] and S. epidermidis 
from blood stream infection in Belgium [123].  
Coagulase-negative staphylococci (CoNS), particularly Staphylococcus epidermidis, can be 
regarded as potential reservoirs of resistance genes for pathogenic strains [124].  Since these 
genes are usually located on plasmids and Staphylococci species including S. aureus co-
colonise an ecological niche at the same time, the genes can easily transfer between same or 
different bacterial species through transformation, conjugation or transduction [112]. 
 
 
1.13 Azithromycin interventions on S. aureus carriage and resistance 
Azithromycin is a macrolide antibiotic belonging to the azalide subclass [125].  Structurally, 
azithromycin is related to erythromycin but has a broader spectrum of antibacterial activity, 
improved tissue penetration and a more favourable pharmacokinetic profile [126].  
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Azithromycin prevents bacteria from growing by interfering with their protein synthesis.  It 
binds to the 50S subunit of the bacterial ribosome and thus inhibits translation of mRNA [127].   
Azithromycin has been used in mass drug administration (MDA) campaigns to control 
trachoma in different countries in Africa [128-131].  Such campaigns have beneficial effects 
beyond the target disease.  In a study in Ethiopia, MDA with azithromycin for trachoma 
control reduced all-cause mortality in 1-9 years old children by 49% [132] and in The Gambia 
MDA reduced asymptomatic pneumococcal carriage by 24.2% in a rural population within a 
space of just one month [133].  Azithromycin has also been used during pregnancy.  
Randomized clinical trials conducted in Malawi and Papua New Guinea have shown that 
azithromycin may help to prevent low birth weight when given in combination with 
sulphadoxine pyremithamine during the second and third trimester of pregnancy [134, 135]. 
Azithromycin interventions have been shown in a number of clinical trials and MDA to 
significantly reduce carriage of S. aureus but also associated with increased prevalence of 
azithromycin resistance S. aureus.  There does not appear to be much data on the impact of 
azithromycin interventions and emergence of macrolide resistant S. aureus in the African sub 
region.  However, in Papua New Guinea, the proportion of azithromycin resistant S. aureus 
isolates was significantly higher among pregnant women receiving azithromycin as part of 
intermittent preventive treatment (79.6% [78/98], versus  14.4% [15/104]; P < 0.001) [134].  
In the same region, children living in rural Australia or urban New Zealand with bronchiectasis 
on long term azithromycin treatment for 24 months reports 100% macrolide resistance 
among S. aureus isolates [136].  Among cystic fibrosis patients in Denmark, continuous 
treatment with azithromycin for at least 3 months reduced prevalence of carriage of S. aureus 
but increased macrolide resistant S. aureus (7% to 52.5% p<0.001) [137].  
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In The Gambia, three annual rounds of azithromycin MDA was associated with a short-term 
increase in both prevalence of carriage of azithromycin and inducible resistance to macrolide 
lincosamides and streptogramin B  (MLSB) resistant S. aureus [111]. 
 
1.14 The PregnAnZI 1 trial  
1.14.1 Trial design and objectives  
The PregnAnZI 1 trial was a Phase III, double -blind, placebo controlled randomized clinical 
trial.  As part of this trial, pregnant women in labour attending study health facilities were 
randomized to receive either a single dose of 2 g of oral azithromycin or placebo (ratio 1:1).  
The primary objective of the trial was aimed at reducing bacterial carriage in both mother and 
new-born as bacterial carriage is a necessary step for infection leading to disease hence 
reducing carriage may help to reduce disease. 
 
1.14.2 Study setting  
The PregnAnZI 1 trial was conducted in Bundung, a peri-urban setting located in the western 
region of The Gambia Figure 8. 




Figure 8. The figure shows the map the Gambia and the study site (Bundung maternal and 
child health hospital formerly called Jammeh Foundation for Peace Health Centre) with the 
surrounding catchment settlements. 
 
It is a very densely populated area with majority of the population engaged in a wide range 
of occupations, including working for government services, liberal professions and trading. 
The climate of the area is typical of the sub-Sahel region, with a long dry season from 
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November to May and a short rainy season between June and October.  The main hospital 
called the Bundung Maternal and child health hospital (BMCHH) formerly referred to as the 
Jammeh Foundation for Peace Hospital (JFPH), is approximately 8km from Fajara where the 
main MRC laboratories are located.  The hospital serves a local community of more than 
50,000 inhabitants and manages approximately 5, 000 deliveries per year. 
 
1.14.3 Screening, recruitment and randomization  
Pregnant women attending the JFPH for antenatal care and planning to deliver their babies 
there were introduced to the study.  Interested women were invited to the study office for a 
detailed explanation in the presence of an impartial witness.  Those that gave consent had 
unique sensitization sticker placed on their antenatal card indicating agreement to join the 
study.  When one of the study pregnant women in labour visits the labour ward of the 
hospital, the study nurse confirms she gave consent and also assess her willingness to 
continue participating in the study.  Women aged 18 to 45 years were included except any of 
the following exclusion criteria were found: 
Known HIV infection, any chronic or acute condition that might interfere with the study as 
judged by the research clinician, planned travel out of the catchment area during the 2 
months after delivery (follow-up period), planned caesarean section, known required referral, 
known multiple pregnancy, known severe congenital malformation of the baby, intrauterine 
death confirmed before randomization, known allergy to macrolides, intake of antibiotics in 
the week before randomization. 
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The woman was recruited into the study once eligibility was determined.  This was followed 
by collection of baseline or pre-intervention samples from the mother [nasopharyngeal swab 
(NPS) and vaginal swab]. 
Azithromycin and placebo were provided as tablets packed in blisters labelled from 001 to 
830. Each woman received 2g of azithromycin or placebo.  The time when the drug was taken 
was recorded. The randomization number on the specific blister was written in the spaces 
provided on the particular page of the case report form (CRF).  
 
1.14.4 Ethical approvals  
All study mothers had signed consent during their pre-natal visits before being enrolled into 
the trial.  A local safety monitor (LSM) and a Data Safety Monitoring Board (DSMB) reviewed 
all the serious adverse events (SAE) during the course of the trial.  The trial was monitored by 
an independent clinical trials monitor.  Approval of the study was by the joint Medical 
Research Council at London School of Hygiene & Tropical Medicine /Gambia Government 
Ethics Committee. 
 
1.14.5 Sample collection and storage 
Following delivery, women and new-born pairs were then followed for 8 weeks collecting 
nasopharyngeal swabs (NPS), breast milk (BM) and vaginal swabs (VS) during the first 4 weeks 
of the follow-up (Table 1).  Following collection, the samples were transported to the 
laboratory within 8hrs and stored at -70°C. 
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Table 1. The different samples types (NPS, vaginal swab and breast milk,) collected from 
mothers and new-borns during a 28 day the follow-up period.  
 















Mother        
Vaginal swab X   X   
NPS X X X  X X 
Breast milk  X X  X X 
New-born       




1.14.6 Bacteriological analysis for NPS, VS and BM samples 
Frozen NPS, BM or VS were allowed to thaw on ice.  Each vial was then vortexed briefly in 
order to homogenise the medium and 50 μl was dispensed onto gentamicin blood agar (GBA) 
(CM0331 Oxoid, UK +5 % sheep blood), mannitol salt agar (MSA)(CM0085 Oxoid, UK) and 
crystal violet blood agar (CVBA)(CM0085 Oxoid, UK +0.02 % crystal violet) for selective 
isolation of S. pneumoniae, S. aureus and group B streptococci (GBS) respectively.  Alpha 
haemolytic colonies from GBA plates that were optochin sensitive and or bile soluble were 
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confirmed S. pneumoniae.  Pale to golden yellow domed shaped colonies from MSA plates 
that were catalase and Staphaurex™ Plus Latex Agglutination test positives were confirmed 
to be S. aureus.  Presumptive beta-haemolytic colonies from CVBA plates that were catalase 
negative were confirmed to be streptococci and grouped using the Streptex grouping kit 
(Remel R30950501) and ultimately reported as A, B, C, D, F or G. 
 
1.14.7 Antibiotic susceptibility testing 
For each confirmed bacteria, a 0.5 % McFarland’s Standard was made in normal saline.  A 
sterile swab was then immersed into the suspension and then streaked evenly over the 
surface of the Mueller Hinton agar (MHA) with 5 % sheep blood (S. pneumoniae and GBS) and 
MHA without blood (S. aureus) in three directions, rotating the plate 90° to ensure even 
distribution.  Azithromycin resistance was screened by disk diffusion (15 μg azithromycin disc) 
and those intermediate or resistant were determined by E-test following the clinical and 
laboratory standard institute (CLSI) 2014 guidelines for the performance of test and 
interpretation of results: (i) S. aureus isolates with E-test values ≥8 μg/ml were reported as 
resistant whilst values <8 μg/ml ≥ 4 μg/ml as intermediate resistant; (ii) S. pneumoniae/GBS 
isolates with E-test values ≥2 μg/ml were reported as resistant whilst values <2 μg/ml ≥ 1 





33 | P a g e  
 
1.14.8 PregnAnZI 12 months cross-sectional  
Between November 2014 and May 2015, children aged 12 months (range 11-13 months) 
whose mothers had participated in the PregnAnZI 1 trial were visited at home and their 
parents re-consented by a trained nurse blinded to the treatment allocation.  NPS were 
collected using calcium alginate (Expotech USA Inc.) swab as described previously [138].  In 
brief, each swab was immediately placed into a vial containing skim milk-tryptone-glucose-
glycerol (STGG) transport medium and then into a cold box before being transported to the 
MRC Laboratories within 8 hours [139].  Upon receipt in the laboratory, the tubes were 
vortexed for a minimum of 20 seconds before being stored in freezers at -70ºC.  
 
1.14.9 Results  
Prevalence of nasopharyngeal carriage of S. aureus, GBS or S. pneumoniae in the new-borns 
at day 6 was lower in the intervention arm (28.3% versus 65.1% prevalence ratio 0.43; 95% CI 
0.36–0.52, p <0.001).  At the same time-point, prevalence of any of the above three bacteria 
in the mother was also lower in the azithromycin group (nasopharynx, 9.3% versus 40.0%, p 
<0.001; breast milk, 7.9% versus 21.6%, p <0.001; and the vaginal tract, 13.2% versus 24.2%, 
p <0.001) [56]. 
Similarly, prevalence of S. aureus carriage was also less common among women (i.e. NPS, VS 
and BM samples) and in new-borns (i.e. NPS) from the azithromycin arm during at least 4 
weeks following the intervention.  At day 6 (primary endpoint of the trial), the prevalence of 
nasopharyngeal carriage of S. aureus in new-borns was 27.5% in the azithromycin arm versus 
63.3% in the placebo arm [prevalence ratio (PR)=0.43 95%CI 0.36-0.52] Figure 9a [56].  Among 
mothers, S. aureus nasopharyngeal carriage was also lower in the azithromycin arm during 
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the 4 weeks following the intervention (at day 6, 7.8% compared to 27.2% in the placebo arm 
PR=0.29 95%CI (0.20-0.42)] Figure 9b.  The same observations were made between arms for 




























Prevalence of carriage of S. aureus during follow up period in new-borns NPS 
among all new-borns.  Carriage was similar at day 0, decreased significantly in the 
intervention arm during the follow up period  
p < 0.001 































Prevalence of carriage of S. aureus during follow up period in mothers NPS 
among all study mothers.  Carriage was similar at day 0, decreased significantly in the 
intervention arm during the follow up period  
p < 0.001 



































Prevalence of carriage of S. aureus during follow up period in mothers breast 
milk among all study mothers.  Carriage was similar at day 0, decreased significantly in 
the intervention arm during the follow up period  





































Prevalence of carriage of S. aureus during follow up period in mothers’ 
vaginal track among all study mothers.  Carriage was lower both at day 0 and day 8 
in the intervention. 
p < 0.026 
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On the other hand, there was a significant increase in the prevalence of azithromycin resistant 
S. aureus in the nasopharynx of neonates; from 0.7% at day 0 to 16.7% at day 28 Fig 10a.  
Among mothers, nasopharyngeal prevalence of azithromycin resistant S. aureus carriage was 
also higher in the azithromycin arm with 1.4% at day 0 to 12.6% at day 28 Fig 10b. 
Observations made between arms for breast milk or vaginal samples followed the same 






Figure 10a Prevalence of azithromycin resistant S. aureus carriage during follow up in new-
borns’ NPS among all new-borns.  Carriage was similar at day 0 and increased in the 





























Figure 10b Prevalence of azithromycin resistant S. aureus carriage during follow up in 
mothers’ NPS among all study mothers.  Carriage was similar at day 0 and increased in the 

























p < 0.001 






Figure 10c Prevalence of azithromycin resistant S. aureus carriage during follow up in 
mothers’ breast milk among all study mothers.  Carriage was similar at day 0 and increased 































Figure 10d Prevalence of azithromycin resistant S. aureus carriage during follow up in 
mothers’ vaginal track among all study mothers.  By day 8 almost all isolates were resistant 



























p < 0.001 
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In a post hoc analysis, it was observed that the trial showed a significant reduction in clinical 
conditions such as mastitis, puerperal sepsis, related infections among mothers and any kind 
of infection among new-borns in the azithromycin arm compared to those in the placebo arm 
Fig 11 [140].   
 
Figure 11. Infection rate among mothers (mastitis and puerperal sepsis) and new-borns (skin 
and any kind of infection) in the azithromycin or placebo arms of the PregnAnZI trial during 8 
weeks of follow up reproduce from [140].  Rates were lower for both mothers and new-borns 
in the intervention arm  
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Incidence of purulent conjunctivitis due to bacterial infection was also lower in the 
azithromycin arm 1.2% vs. 3.8% OR 0.31 95%CI (0.12-0.82) and S. aureus being the most 
common bacterial species associated with these infections [112] Table 2. 
 
Table 2 Incidence of bacterial conjunctivitis reported by trial arm 
Characteristic Azithromycin arm 
(N = 419) n (%) 
Placebo arm 
(N = 424) n (%) 
OR (95% CI) p-
value 
Purulent discharge 18 (4.3) 22 (5.2) 0.82 (0.44,1.54) 0.628 
Any bacteria 
detected 
5 (1.2) 16 (3.8) 0.31 (0.12,0.82) 0.025 
Any gram-positive 4 (1.0) 14 (3.3) 0.28 (0.10,0.82) 0.029 
  S. aureus 4 (1.0) 12 (2.8) 0.33 (0.11,0.98) 0.074 
  S. pneumoniae 0 (0.0) 2 (0.5) 0.00 (0.00,1.94) 0.499 
Any gram-negative 1 (0.2) 6 (1.4) 0.17 (0.00,1.06) 0.123 
  H. influenzae 0 (0.0) 3 (0.7) 0.00 (0.00,1.29) 0.249 
  M. catarrhalis 0 (0.0) 3 (0.7) 0.00 (0.00,1.29) 0.249 
  N. gonorrhoeae 1 (0.2) 1 (0.2) 1.01 (0.00, NA) 1.00 
  C. trachomatis 0 (0.0) 0 (0.0) – – 
Bacterial co-
infectiona 
0 (0.0) 4 (0.9) 0.00 (0.00,0.97) 0.124 
aBacterial co-infections: (i) S. aureus and H. influenzae; (ii) S. pneumoniae and H. influenzae; (iii) S. aureus and N. 
gonohorreae (iv) M. catarrhalis, S. pneumoniae and H. influenzae 
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1.14.10 Summary of results  
As a summary, 2g of azithromycin given to women in labour had a strong effect on prevalence 
of S. aureus carriage in mothers and their babies and had an effect on non-severe neonatal 
and maternal infections.  Although the intervention has a potential important public health 
impact, on reducing maternal and neonatal infections, the effect of the intervention on long 
term carriage of pathogenic bacteria and antibiotic resistance, especially for S. aureus, needs 
serious attention. This will be the focus of my PhD and the investigations undertaken in order 
to examine those effects will be outlined in subsequent chapters of this thesis. 
 
1.15 PhD Study rationale 
The PregnAnZI 1 trial aimed at lowering bacterial carriage both in the mother and her new-
born, a necessary step to reducing maternal and neonatal sepsis.  Results of the trial revealed 
that intrapartum azithromycin decreased carriage of S. aureus, group B Streptococcus and 
Streptococcus pneumoniae during the entire neonatal period for both the women and the 
new-borns.  However, it also resulted to increased prevalence of azithromycin resistant S. 
aureus during the 28-day follow-up period from both mothers and new-borns. 
A prophylactic intervention such as intrapartum oral azithromycin may eventually be 
implemented only after carefully balancing the benefits versus the risks.  One of the major 
unintended consequences, or risks, of antibiotic prophylaxis is the emergence of antibiotic 
resistant bacterial species which can potentially spread within the community leading to 
infections that become more difficult to treat. 
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Among the three bacteria tested as part of the PregnAnZI 1 trial, azithromycin resistance to 




















Intrapartum oral azithromycin prophylaxis has been shown to be effective in reducing 
maternal and neonatal bacterial colonisation and clinical infections in The Gambia.  However, 
it was also associated with the emergence of azithromycin resistant bacterial species 
especially for S. aureus an important pathogen responsible for both maternal and neonatal 
infections leading to high morbidity and mortality in The Gambia. 
The aims of this PhD are to investigate the long-term impact of such intervention on S. aureus 
colonisation and antimicrobial resistance, molecular epidemiology of azithromycin resistant 
S. aureus as well as the prevalence of staphylococcal nasopharyngeal macrolide resistant 
genes among mother and babies following the intervention. 
 
2.2 Objectives  
The specific objectives are as follows: 
1) To determine a point prevalence of nasopharyngeal carriage and azithromycin 
resistance for S. aureus at the age of 12 months among children whose mothers 
participated in the PregnAnZI 1 trial. 
2) To characterise the population of azithromycin resistant S. aureus recovered from 
mothers and babies using genomics to identify the genetic markers of azithromycin 
resistance; and also explore the potential roles of clonal replacement and 
transmission of azithromycin resistant S. aureus at an individual subject level. 
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3) To evaluate the prevalence of nasopharyngeal macrolide resistant genes during 
infancy induced by intrapartum azithromycin among infants in the azithromycin arm 





















3.1 Media preparation 
3.1.1 Mannitol Salt agar  
Mannitol salt agar (MSA) is both a selective and differential medium used in the isolation of 
Staphylococci.  It contains 7.5% sodium chloride and thus selects for those bacteria which can 
tolerate high salt concentrations.  MSA also distinguishes bacteria based on the ability to 
ferment the sugar mannitol, the only carbohydrate present in the medium. 
In preparation, 111g was dissolved in 1litre of distilled water and mixed until a homogenous 
mixture was obtained.  The mixture was then autoclaved at 121°C for 15 min in order to 
sterilise the medium and then allowed to cool to a temperature of about 45°C.  A 20-25ml of 
the ready media was then poured into Petri dish plates in an air flow safety cabinet and 
allowed to set.  The culture media plates were stored upside down at 2-8°C to reduce chances 
of contamination.  Prior to using the plates, they were dried in the oven at 50°C for 10min to 
prevent bacterial swarming on the plates.  Each batch of plates undergoes quality control by 
testing for both sterility and growth performance using American type culture controls (ATCC) 
bacterial strains. 
 
3.1.2 Blood agar (BA)/Gentamicin Blood agar (GBA) 
Blood agar (BA) consists of an enriched agar base to which blood cells are added. Besides 
providing enrichments for the growth of fastidious pathogens, Blood agar can be used to 
detect haemolytic properties.  Gentamicin Blood Agar (GBA) is a Columbia based blood agar 
supplemented with gentamicin antibiotic at a concentration of 10µg/ml.  It is a selective 
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media for isolating S. pneumoniae. Gentamicin antibiotic suppresses the growth of 
staphylococci, group A streptococci, and Gram-negative bacilli for example E. coli. 
In preparation, 39g of Columbia agar was added to 1 litre of distilled water, mixed thoroughly 
to dissolve the medium completely and then autoclaved at 121°C for 15min.  The media was 
allowed to cool to a temperature of around 45°C.  50 ml of defibrinated sheep blood (5%) was 
then added to the media and mixed gently to avoid the formation of bubbles.  20-25ml of the 
mixture poured into petri dish in a laminar flow safety cabinet to avoid contamination.  In the 
case of GBA, 0.5ml of gentamicin (10mg/ml) was added to media following the addition of 
defibrinated sheep blood prior to pouring into petri dish. 
 
3.1.3 Mueller Hinton agar (MHA)/ Mueller Hinton agar with 5% sheep Blood 
MHA is the medium of choice for antibiotics sensitivity testing for rapidly growing aerobic or 
facultative anaerobic bacterial pathogens such as streptococci, staphylococci, members of the 
enterobacteriaceae, and aerobic Gram-negative rods: e.g. Pseudomonas spp. MHA with 5% 
sheep blood is recommended for susceptibility testing of Streptococcus pneumoniae.  The 
agar is non-selective and differential.  It contains starch known to absorb toxins released from 
bacteria, so that they do not interfere with the antibiotic activity.  The agar is not compacted 
together which allows for better diffusion of the antibiotic producing a more accurate zone 
of inhibition. 
In the preparation, 38g of MHA powder (Oxoid, UK) was added to 1 litre of distilled water and 
mixed thoroughly to dissolve the medium completely without the formation of bubbles.  The 
mixture was then autoclaved at 121°C for 15 minutes before allowing to cool to 45°C.  In the 
case of MHA with sheep blood, 50ml of defibrinated sheep blood was added to the medium 
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and mixed thoroughly but gently to avoid bubbles.  A volume of 20-25ml of the ready media 
then poured into Petri dish in laminar flow safety cabinet.  The medium was then allowed to 
set for at least 30 minutes at room temperature before storing at 2-8oC. 
 
3.1.4 Normal saline (0.85%) 
Normal Saline is a useful diluent used in laboratories to maintain cell integrity and viability.  It 
lacks the properties that may interfere with biochemical reactions and/or antibiotic 
susceptibility tests when used to suspend and wash bacterial cells in the lab. 
In preparation, 4.25g of salt (1 tablet Oxoid code BR053G) was dissolved in 500ml of distilled 
water and sterilised by autoclaving at 121°C for 15minutes. 
 
3.2 Isolation and identification of S. aureus and S. pneumoniae  
Isolation and identification of both S. aureus and S. pneumoniae were performed following   
standard microbiology techniques.  In brief, 50 μl of thawed skim milk, tryptone, glucose, and 
glycerol (STGG) containing nasopharyngeal swab was dispensed onto gentamicin blood agar 
(GBA) (CM0331 Oxoid, UK + 5% sheep blood) and mannitol salt agar (MSA) (CM0085 Oxoid, 
UK) for selective isolation of S. pneumoniae and S. aureus respectively.  The inoculum was 
streaked in four quadrants (Figure 12) using a sterile loop to obtain discrete colonies and then 
incubated.  
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Figure 12 Streaking of the primary inoculum on to an agar plate to obtain discrete colonies 
  
3.2.1 Streptococcus pneumoniae 
After 20–24 hours incubation at 37 °C with 5% CO2, the GBA plates were examined for growth 
and haemolysis.  Morphologically distinct alpha haemolytic colonies were selected and sub-
cultured on to another blood agar (BA) to obtain pure growth and screened for optochin 
susceptibility by measuring the zone of inhibition around the optochin disc [139].  Suspected 
S. pneumoniae isolates with optochin zones of inhibition ≥ 14 mm were confirmed to be 
pneumococci (Figure 13), those 7-13 mm were test further for bile solubility and isolates less 
than 7 mm were considered to be species other than pneumococci.  
 
Figure 13. Confirmed S. pneumoniae isolate showing alpha haemolysis on a blood agar 
plate. 
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3.2.2 Bile solubility test  
Bile solubility test was performed on all suspected S. pneumoniae isolates with optochin zone 
diameters measuring 7-13 mm.  In the process, several colonies of the suspected S. 
pneumoniae were emulsified in a sterile bijoux bottle containing 4ml of physiological saline 
to obtain a turbidity equivalent to 5 McFarland standards.  2ml of the suspension was then 
aliquoted into a new sterile bijoux bottle.  The same procedure was repeated for the S. 
pneumoniae ATCC 49619 strain for use as a positive control for the experiment.  One of the 
bijoux bottles was marked “Test” and the other “Control”.  The same applies to the bijoux 
bottle containing the ATCC strain.  Two drops of the bile reagent (sodium deoxycholate) were 
added to the tubes marked “Test” and two drops of distilled water were also added in the 
tubes marked “Control” mixed and incubated at 37°C for 2 hours.  After the incubation period, 
the tubes were checked for clearing of turbidity.  A positive bile solubility test results to 
clearing of the turbidity whilst the tubes containing distilled water will remain turbid after 2 
hours incubation.  It should be noted that the test should not be performed on old cultures, 
as the active enzyme called autolysin may be lost. 
 
3.3 Staphylococcus aureus 
Following 48 hours of incubation at 37°C, MSA plates were examined for typical Staphylococci 
colonies.  Pale to golden yellow domed shaped colonies 1–2 mm in diameter (Figure 14) were 
cultured onto blood agar to obtain pure growth.  A rapid latex agglutination test for the 
identification of S. aureus was performed using the Staphaurex® plus kit (Oxoid UK Cat no. 
OXR30950201).  The test detects clumping factor, protein A and/or surface antigens 
characteristic of S. aureus.  In the process, 2-3 colonies of pure suspected S. aureus were 
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collected with the aid of an applicator stick and mixed with a drop of the positive reagent and 
a negative reagent separately.  Both mixtures were rugged for about 2 minutes.  Agglutination 
with the positive reagent and none with negative indicates a positive test.  Positive isolates 
were confirmed to be S. aureus (Figure 14). 
 
Figure 14 Confirmed S. aureus isolate on mannitol salt agar plate showing fermentation of 
mannitol resulting in the medium changing from pink to yellow colour   
 
3.4 Antibiotic susceptibility testing  
3.4.1 Disc diffusion and Epsilometry test (Etest) 
Antibiotic susceptibility was performed for both S. aureus and S. pneumoniae.  In brief, 
following the isolation and confirmation of the bacteria, a sterile loop was used to touch 3-5 
well-isolated colonies of similar morphological appearance and transferred into 2.5ml normal 
saline until visible turbidity equal to 0.5 McFarland’s Standard was obtained.  A sterile swab 
was then immersed into the suspension and gently press on the sides of the bijou bottle to 
remove excess fluid.  The swab then evenly streaked over the surface of the medium in three 
directions, rotating the plate 90 °C to ensure even distribution.  Then the plate was incubated 
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at room temperature for 15min for the moisture to be absorbed by the medium.  A disc 
dispenser or sterile forceps was then used to apply the antibiotic discs.  The discs were placed 
about 15mm from the edge of the plate and less than 25mm between discs.  Plates were 
incubated within 15-30 minutes of discs application.  Resistance was initially screened using 
the following antibiotic discs: azithromycin (15 μg), chloramphenicol (30μg), clindamycin 
(2μg) and erythromycin (15μg).  In addition, only S. pneumoniae isolates were screened for 
trimethoprim-sulfamethoxazole (1.25/23.75μg) and oxacillin (1μg) susceptibility and S. 
aureus for cefoxitin (30μg) susceptibility. Table 3 shows the cut off values used in the 
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Table 3 showing the Disc diffusion cut offs for the different antibiotics (CLSI 2017)  
Bacteria  Antibiotic Disc diffusion cut off(zone of growth 
inhibition in mm) 
S. aureus   Sensitive Intermediate Resistant 
 Azithromycin 15 μg ≥18 14-17 ≤13 
 Chloramphenicol 30 μg ≥18 13-17 ≤12 
 Clindamycin 2 μg ≥21 15-20 ≤14 
 Erythromycin 15 μg ≥23 14-22 ≤13 
 Cefoxitin 30 μg ≥25 - ≤24 
S. pneumoniae      
 Azithromycin 15 μg ≥18 14-17 ≤13 
 Chloramphenicol 30 μg ≥21 - ≤20 
 Clindamycin 2 μg ≥19 16-18 ≤15 










 Oxacillin 1μg  ≥20  - - 
 
 
All isolates that were assessed as of intermediate or resistant by the disc diffusion method 
were tested further using the E-test for confirmation except those isolates resistant to 
cotrimoxazole.  For these isolates, only a random selection of 90 were confirmed by the E-
test due to lack of funds. Sample preparation for E-test was performed exactly as described 
above for the disc diffusion method.  However, only a single E-test strip was added per plate 
prior to overnight incubation.  After the incubation period a symmetrical inhibition ellipse was 
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produced by the strip on the plate.  The MIC value is read from the scale in terms of µg/mL 
where the ellipse edge intersects the strip.  Susceptibility to the different antibiotics was 
determined following the clinical and laboratory standards institutes  guidelines (CLSI) Table 
4 [141]. 
 
Table 4 Showing the E-test cut offs for the different antibiotics (CLSI 2017)  
Bacteria  Antibiotic E-test cut-off 
S. aureus   Sensitive Intermediate Resistant 
 Azithromycin 15 μg ≤2 4 ≥8 
 Chloramphenicol 30 μg ≤8 - ≥16 
  Clindamycin 2 μg ≤0.5 1-2 ≥4 
 Erythromycin 15 μg ≤0.5 1-4 ≥8 
 Cefoxitin 30 μg ≤4 - ≥8 
S. pneumoniae      
 Azithromycin 15 μg ≤0.5 1 ≥2 
 Chloramphenicol 30 μg ≤4 - ≥8 
 Clindamycin 2 μg ≤0.25 0.5 ≥1 










 Oxacillin (1μg)  ≤2 4 ≥8 
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3.4.2 Vitek 2 
The VITEK 2 is an automated microbiology system that utilizes a growth-based technology.  
The system accommodates colorimetric reagent cards that are incubated and interpreted 
automatically.  The card has 64 wells that is barcoded with information on card type, 
expiration date, lot number and unique card identification number.  Different test kits are 
available including ID-GN (Gram-negative bacillus identification), ID-GP (Gram-positive cocci 
identification), AST-GN (Gram-negative susceptibility) and AST-GP (Gram-positive 
susceptibility).  The Vitek 2 ID-GP card identifies 124 species of staphylococci, streptococci, 
enterococci and a select group of Gram-positive organisms within 8 hours or less. 
All S. aureus and S. pneumoniae isolates found to be resistant by E-test to azithromycin, 
erythromycin, or clindamycin were retested using the VITEK-2 (bioMérieux, France). The 
VITEK-2 results were considered definitive.  In the process, a new virtual cassette was selected 
and the barcode for a Gram-positive cassette was scanned followed by entry of sample 
number in the accession number column.  The organism ID name was selected from the drop-
down list in the organism field.  A 0.5-0.63 McFarland suspension was prepared in 0.45% 
sterile saline.  Following this 280μl of the suspension was aliquoted and dispensed into 
another tube containing 3ml of 0.45% sterile saline.  The AST card was then turned around so 
that the filler tube was directly in contact with the suspension.  The complete unit was then 
inserted in the Vitek 2 machine first into a chamber where the suspension was loaded into 
the cassette and then into another chamber were the susceptibility test was performed.  The 
procedure was repeated for all the samples with a maximum of ten samples per cassette and 
the entries saved.  The results of the susceptibility testing for the antibiotic were retrieved 
from the computer the next day Figure 15. 




Figure 15  Vitek 2 machine with computer sourced from 
https://www.dksh.com/media/953/997/3da2e-vitek2-compact-biomerieux-,0.png for 
antibiotic susceptibility and analysis of the results 
 
3.5 DNA extraction 
3.5.1 DNA extraction from pure S. aureus culture   
Genomic DNA was extracted using the Sigma GenEluteTM Bacterial Genomics DNA Kit NA2120 
1KT with some slight modifications.  A single isolated S. aureus colony was introduced in to 
10ml of brain heart infusion broth (BHI) and incubated overnight.  Following incubation in BHI 
broth, 0.5ml of the cell culture was dispensed into an eppendorf tube.  The tube was then 
centrifuged for 1min @ 13,000 x g.  This was followed by washing in 1ml phosphate buffered 
saline PBS and centrifuged for 2min @ 5,000 g.  The cells were then suspended in 200µl of 
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lysis buffer comprising 200µl of enzymatic lysis buffer (20mM Tris-HCl pH 8.0, 2mM sodium 
EDTA and 1.2% Triton x-100), 9mg of lysozyme and 5µl of lysostaphin 2mg/ml.  The mixture 
was incubated in a 37°C water bath for 20min.  20µl of RNAse A was added and incubated for 
further 10minutes.  20 μl of the Proteinase K solution (20mg/ml) was added to the sample, 
followed by 200 μL of Lysis solution C (B8803).  The mixture was vortexed thoroughly (about 
15 seconds) and incubated at 55 °C for 10 minutes.  200 μl of ethanol (95–100%) was then 
added to the lysate and mixed thoroughly by vortexing for 5–10 seconds to obtain a 
homogeneous mixture.  The entire contents of the tube were then transferred into the 
binding column and centrifuged at ≥ 6500 × g for 1 minute.  The collection tube containing 
the eluate was discarded and the column placed in a new 2 ml collection tube.  The columns 
were washed twice using wash solution 1 and 2 respectively.  200 μl of the Elution Solution 
(B6803) was directly added onto the centre of the column and incubated at room 
temperature for 5 min before centrifuging for 1 minute at ≥ 6500 × g to elute the pure DNA. 
 
3.5.2 Extraction of total nucleic acid from NPS 
Total nucleic acid was extracted directly from NPS using QIAamp DNA Mini Kit (QIAGEN, 
United Kingdom) protocol with some modifications.  Frozen nasopharyngeal swabs in STGG 
medium were initially thawed at room temperature, vortexed briefly and 200μl of the sample 
added to 200μl of lysis buffer (TE buffer, lysozyme 30mg/ml, mutanolysin 50U/ml, lysostaphin 
200μg/ml) before being incubated at 37°C for 1 hour.  AL buffer and proteinase K were then 
added and incubated further at 56°C for 1 hour. After the second incubation, 250µl of ethanol 
was added and the whole suspension transferred into a spin column and centrifuged at 8000 
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rpm for 1 minute. The columns were washed twice before eluting pure total nucleic acid in 
100µl of the elution buffer and stored at -20°C until use.  
 
3.6 Nano Drop 
Following extraction of DNA or total nucleic acid, Nanodrop was performed on all of the 
samples in order to obtain the nucleic acid yield but also the purity of the DNA extract.  In the 
process, the nanodrop software was opened on the computer by clicking the icon ND100 and 
nucleic acid was selected.  The sensor pedestal cleaned and 1ul of RNAse free water added 
without generating bubbles to initialise the equipment.  This was followed by blanking the 
equipment by adding 1ul of the elution buffer to the sensor pedestal.  Then, the number of 
each sample was entered ensuring DNA was selected as sample type.  The ratios 260/280 
(1.8-2.1) and 260/230 (1.8-2.0) were used to determine protein and organic contamination of 
sample respectively. 
 
3.7 Qubit assay  
The Qubit assays use target-selective dyes that emit fluorescence when bound to DNA, RNA 
or protein.  It is less prone to over estimation of sample concentration due to contaminants 
such as salts, solvents, detergents, proteins, free nucleotides.  The Qubit was used to more 
accurately determine concentration of DNA extracted from pure S. aureus cultures during the 
library prep stage of the whole genome sequencing.  In the process, 1μl of Qubit reagent was 
added to 199μl of Qubit buffer to obtain the working solution.  Following the preparation of 
the working solution for the total number of samples and the two standards, 10μl of standard 
1 then standard 2 were each added to 190μl of the Qubit working solution, vortexed briefly 
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and incubated at room temperature for 2min before being read.  Following calibration, 198μl 
of Qubit working solution and 2μl each sample were added, incubated for 2min and 
concentration measured in ng/μl Figure 16. 
 
 
Figure 16 The Qubit assay and the reagents(buffers and standards)  sourced from 
https://www.thermofisher.com/content/dam/LifeTech/global/life-sciences/images/qubit-
assays.png for DNA quantification 
 
3.8 Cloning and transforming ermC and msr(A) genes  
Vector pRAB11 was initially amplified with the following primers to create a backbone for 
SLiCE (seamless ligation cloning extract) cloning using the following primer pairs: pRAB11_F 
and pRAB11_R.  The ermC_2/13 and msr(A) genes were also amplified using ermC_pRAB11_F 
ermC_pRAB11_R and msr(A)_Saur_pRAB_F msr(A)_Saur_pRAB_R primers respectively.  The 
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primer sequences are shown in Table 5.  The PCR fragments were ligated using SLiCE and 
transformed into IM08 competent E. coli cells.  The transformed cells were plated on Luria 
broth (LB) agar with 100µg/ml ampicillin and incubated overnight at 37°C.  Successful 
transformation was confirmed by colony PCR from colonies growing on the LB agar.  The 
confirmed colonies were cultured overnight, and plasmids extracted using QIAGEN mini prep 
kit.  Plasmids carrying ermC or msr(A) gene were electroporated into an azithromycin 
sensitive S. aureus strain (S70065MN00) and plated on LB agar with 10µg/ml chloramphenicol 
before incubating overnight.  Colonies were screened to confirm the presence of either ermC 
or msr(A) genes using the above primers. 
 
Table 5 Showing the primer sequences for the vectors and macrolide resistant genes   
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3.9 Bacterial conjugation 
The donor (S80062MN28; azithromycin MIC 192 μg/ml, rifampicin  MIC <1 μg/ml; fusidic acid 
MIC <1 μg/ml) and recipient strain that was induced to high level rifampicin and fusidic acid 
resistance through serial passage (S70065MN00, azithromycin MIC 1 μg/ml, rifampicin MIC 
>32 μg/ml; fusidic acid MIC >32 μg/ml) were mixed on a membrane filter (Millipore) with a 
donor-to-recipient ratio of 1:1. Plates were incubated overnight at 37°C. The bacterial cells 
were resuspended in PBS and spread on BHI agar plates containing the appropriate 
antibiotics. To quantify conjugative transfer efficiencies, dilutions were plated on BHI media 
containing antibiotics for the selection of; donor cells, recipient cells and plasmid containing 
recipient cells. Trans-conjugants were selected on plates containing azithromycin, rifampicin 
and fusidic acid all at 32 μg/ml. All conjugation assays were performed in duplicates. Control 
conjugation experiments were performed with the donor strain only, and no spontaneous 
resistant colonies were observed. The resistance profile of donor, recipient and 
transconjugant are summarized in Table S1. 
 
3.10 PCR 
The primers for the amplification of the macrolide resistant genes [msr(A)_F 
ATCCAATCATTGCACAAAATCTAACATT, msrA_R TAAATAGCTTCAAGTAAAGTTGTCTTACC and 
ermC_F CTTGTTGATCACGATAATTTCCAAG, ermC_R TTGTATTCTTTGTTAACCCATTTCATAAC]  
and a S. aureus thermostable nuclease nuc gene [ nuc_F GCGATTGATGGTGATACGGTT nuc_R 
AGCCAAGCCTTGACGAACTAAAGC ] were designed using an online primer design tool 
(Primer3plus http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and 
synthesised by Metabion, Germany.  Primers sets were diluted to a final concentration of 
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10μM and assayed in 20μl PCR reaction volume containing 1µl of each primer, 10μl 2x Phire 
Green Hot Start II PCR (Thermo Scientific, United Kingdom) reaction buffer, 7μl nuclease 
water and 1µl of the sample.  The cycling conditions included an initial denaturation at 98°C 
for 30 seconds, 35 cycles of denaturation at 98°C for 5 seconds, annealing at 52°C for 5 
seconds and extension at 72°C for 10 seconds with a final extension at 72°C for 1 minute.  




The PCR products were analysed using QIAxcel advanced Screen gel 1.5.0 (QIAGEN, UK) Figure 
17.  The QIAxcel enables separation and analysis of a variety of nucleic acids including single 
or multiple PCR fragments, DNA digested with restriction endonucleases, synthesized 
oligonucleotides, total RNA and cRNA.  The setup allows the user to define run parameters 
and preselect DNA size markers.  
For the analysis of amplified PCR products of the gene targets, a tolerance rate of ±15% of the 
expected band sizes [(msr(A) 145bp, ermC 398bp and nuc 279bp)] and DNA size markers 
(1000bp and 15bp) were used.  The relative fluorescence unit (RFU) was determined to be 








Figure 17 The QIAxcel procedure for the separation of nucleic acid molecules, detection, 
photomultiplication before conversion of the data to an electropherogram and gel image by 
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3.12 Whole genome sequencing and bioinformatic analysis 
Staphylococcus aureus genomic DNA was extracted using the Sigma GenEluteTM Bacterial 
Genomics DNA Kit NA2120 1KT.  DNA libraries were prepared using the Nextera XT kit 
(Illumina, San Diego, CA, United States), and sequenced on the Illumina Nexseq platform using 
2 × 150-bp chemistry.  The raw reads were initially quality controlled to obtain information 
such as minimum and maximum read lengths, GC content, average quality and depth of 
coverage.  Short-read sequence data was assembled using SPAdes v3.11.1 [142], excluding 
the pre-assembly error correction, including a post-assembly error correction and a minimum 
coverage threshold of “5” to remove contaminants.  A hybrid assembly approach using both 
long- and short-read sequence data was utilised to assemble isolate S80062MN28, performed 
using unicycler v0.4.6 with the assembly mode set as “bold”[143].  Annotation of plasmid 
pS80062MN28 was performed using prokka v1.13.3[144], preferentially annotating from 
plasmid pJSA01 (accession AP014922.1)[145].  Comparative alignment of plasmid sequences 
was performed using the Artemis Comparison Tool v17.0.1, excluding matches ≤ 100 bp in 
length[146].  In silico MLST and antibiotic resistance gene detection was performed on draft 
assemblies and complete genomes using mlst v2.10 (https://github.com/tseemann/mlst) and 
abricate v0.8.10 (https://github.com/tseemann/abricate), using the NCBI antimicrobial 
resistance database (ncbi: updated 20-Sept-2018) and the virulence factor database (vfdb: 
updated 14-Aug-2018). 
For the phylogenetic analysis, short-read sequence data was mapped to the complete 
genomes of six S. aureus reference genomes (genome accessions: CP026964.1 [ST1]; 
CP026968.1 [ST5]; CP012970.1 [ST8]; LS483319.1 [ST15]; CP024998.1 [ST152]; LS483314.1 
[ST669]), each selected for being the most closely related complete genome for each ST 
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identified in the study population.  Read mapping and calling of single nucleotide 
polymorphisms (SNPs) was completed using snippy v4.3.5 
(https://github.com/tseemann/snippy).  Whole genome alignments were used to construct 
maximum likelihood (ML) phylogenetic trees with iqtree v1.6.5 [147].  Model selection was 
used to find the best nucleotide substitution model for each alignment (chosen according to 
the Bayesian Information Criterion): this was either the HKY+F for ST5 and ST15 [148], or the 
F81+F for ST1, ST8, ST152 and ST669 [149].  Alignments composed of greater than 5 isolates 
(ST5 and ST15) were subjected to 1000 ultra-fast bootstrap replicates [150].  ML trees were 
visualized using FigTree v1.4.3 (http://tree.bio.ed.ac.uk/software/figtree/).  Core pairwise 
SNP distances were calculated using an in-house pearl script. 
The global S. aureus phylogeny was constructed using publicly available genomes and 
metadata as described in Guerillot et al. [151].  The 66 isolates sequenced as part of this study 
were added, together with 28 newly sequenced S. aureus genomes from Africa (downloaded 
from the Staphopia database [152].  The 7191 genomes were mapped to the fully assembled 
reference genome S. aureus NRS384 and core genome alignment of the global collection 
(n=7192), all CC5 isolates (n=2735) or all CC15 isolates (n=179) were generated with snippy 
v4.3.6.  Maximum likelihood phylogenetic trees were inferred with Fast Tree v2.1.8 using the 
generalized time reversible (GTR) model.  Trees were plotted and annotated using the R 
library ggtree [153].  Sub-trees of CC5 and CC15 were generated from the full CC5 or CC15 
phylogenetic trees by extracting only isolates with a tip distance of <23 nodes from the 
isolates sequenced in this study. 
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3.13 Phenotypic testing of transformed S. aureus 
A 0.5M suspension was prepared for each of the wild type (S70065MN00), wild type + empty 
plasmid and wild type + mutants in normal saline.  The suspension was streaked on to Mueller 
Hinton agar using a sterile swab before placing an azithromycin E-test strip and incubating for 
20 hours at 37°C. 
 
3.14 Data management and statistical analysis 
Laboratory results and other personal data including randomization number, date samples 
were collected, lab staff identification were transcribed onto bar-coded forms and submitted 
to data management for entry. The data were entered independently by two data entry clerks 
in OpenClinica (www.openclinica.com) and antibiotic susceptibility data for S. pneumoniae 
were stored in a REDcapTM database.  The data base was then cleaned and verified to ensure 
data quality. 
In the analysis, each of the following antibiotics: azithromycin, chloramphenicol, clindamycin, 
erythromycin, trimethoprim-sulfamethoxazole, oxacillin and cefoxitin the resistant bacterial 
carriage prevalence was compared between trial arms using the chi-square test. This was 
done for both S. pneumoniae and S. aureus.  In addition, I assessed if azithromycin resistance 
up to day 28 post-treatment was associated with resistance 12 months later.  For this analysis, 
only children who were sampled during all five time points in the trial (day 0, 3, 6, 14, 28) and 
were also sampled in the 12-month CSS were included. 
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Fisher exact test was used to compare the prevalence of sequence types or macrolide 
resistance genes between the azithromycin and placebo group.  A P value of 0.05 was used 
as the cutoff for statistical significance. 
Pearson’s χ2 test was used to compare the prevalence and relative fluorescence of macrolide 
resistant genes between arms at birth, at day 28 and at 12 months. The χ2 test was also used 
to test for an association between the resistance genes at day 28. This analysis was stratified 
by trial arm, and a Mantel-Haenszel test was used to test for interaction. P-value ≤ 0.05 was 






















4.2 LONG-TERM IMPACT OF ORAL AZITHROMYCIN TAKEN BY GAMBIAN WOMEN 
DURING LABOR ON PREVALENCE AND ANTIBIOTIC SUSCEPTIBILITY OF 
STREPTOCOCCUS PNEUMONIAE AND STAPHYLOCOCCUS AUREUS IN THEIR INFANTS: 
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Long-term Impact of Oral Azithromycin Taken by 
Gambian Women During Labor on Prevalence and 
Antibiotic Susceptibility of Streptococcus pneumoniae 
and Staphylococcus aureus in Their Infants: Follow-up 
of a Randomized Clinical Trial 
 
Abdoulie Bojang,1 Bully Camara,1 Isatou Jagne Cox,1 Claire Oluwalana,1 Kodou Lette,1 Effua Usuf,1,2 
Christian Bottomley,3 Benjamin P. Howden,4 Umberto D’Alessandro,1,2,5 and Anna Roca1,6  
1Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Fajara; 2Faculty of Infectious and Tropical Diseases and 3Medical 
Research Council Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, United Kingdom; 4Microbiological Diagnostic Unit Public Health 
Laboratory, Department of Microbiology and Immunology, University of Melbourne, Doherty Institute for Infection and Immunity, Victoria, Australia; 5Institute of Tropical 
Medicine, Antwerp, Belgium; and 6Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, United Kingdom  
 
Background.  Oral azithromycin given to women in labor decreases maternal and neonatal bacterial carriage but increases azi-
thromycin-resistant bacteria during at least 4 weeks following the intervention. We assessed the prevalence of bacterial carriage 
and azithromycin resistance 12 months after treatment among study infants.  
Methods.  Nasopharyngeal swabs (NPSs) were collected between November 2014 and May 2015 from children aged 11–13 
months whose mothers had received azithromycin or placebo during labor. Streptococcus pneumoniae and Staphylococcus aureus 
were iso-lated using conventional microbiological methods. Antibiotic susceptibility was determined by disk diffusion and 
confirmed by Etest or VITEK-2.  
Results.  NPSs were collected from 461 children. The prevalence of S. pneumoniae and S. aureus was similar between chil-dren from 
the azithromycin and placebo arms (85.0% vs 82.1%; odds ratio [OR], 1.23 [95% confidence interval {CI}, .73–2.08] for S. pneumoniae 
and 21.7% vs 21.3%; OR, 1.02 [95% CI, .64–1.64] for S. aureus). Prevalence of azithromycin-resistant S. pneumo-niae was similar in both 
arms (1.8% vs 0.9% in children from the azithromycin and placebo arms, respectively; OR, 2.10 [95% CI,  
.30–23.38]); resistance to other antibiotics was also similar between arms. For S. aureus, there was no difference in azithromycin 
resistance between children in the azithromycin (3.1%) and placebo (2.6%) arms (OR, 1.22 [95% CI, .35–4.47]) or resistance to 
any other antibiotics.  
Conclusions.  The higher prevalence of S. aureus azithromycin resistance observed among women treated during labor and 
their babies 4 weeks after treatment had waned 12 months after delivery. Azithromycin intervention did not induce other antibiotic 
resistance to S. pneumoniae or S. aureus.  
Clinical Trials Registration.  NCT01800942.  
Keywords.  azithromycin; S. aureus; S. pneumoniae; resistance; West Africa.  
 
 
Azithromycin is a second-generation broad-spectrum mac-
rolide used to treat infections such as pneumonia, middle ear 
infections, and sexually transmitted infections [1, 2]. 
Azithromycin has also been used in mass drug administra-tion 
(MDA) campaigns to control trachoma in several endemic  
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countries in Africa [3–6]. The impact of these MDA campaigns has 
varied from one country to another [6–8], but when the baseline 
prevalence of trachoma is low, 1 round of MDA with azithromycin 
(MDA-Z) is sufficient to eliminate trachoma [3]. Furthermore, 
MDA-Z may have beneficial effects beyond tra-choma control. In 
rural Gambia, 3 annual rounds of MDA-Z reduced by 24.2% 
asymptomatic pneumococcal carriage for at least 1 month [9] and, 
in Ethiopia, it reduced by 49% all-cause mortality in children aged 
1–9 years [10].  
Azithromycin has also been given in combination with sul-
fadoxine-pyrimethamine (SP) during pregnancy with the aim of 
reducing the prevalence of low birth weight. In Malawi and Papua 
New Guinea, babies born to mothers who received azith-romycin 
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MDA-Z may increase the prevalence of macrolide 
resistance, even after the administration of a single dose. In The 
Gambia, MDA-Z resulted in a short-term increase in 
azithromycin-re-sistant Streptococcus pneumoniae [9], while in 
Tanzania a single dose of MDA-Z increased prevalence of 
resistance for >6 months [13]. The prevalence was also high in 
Ethiopia among children after receipt of several annual doses 
[14] and declined after azithromycin was discontinued [15].  
For Staphylococcus aureus, another common bacterial patho-
gen, there are increasing data on the effect of MDA-Z on resis-
tance. In rural Gambia [3], 3 annual rounds of MDA-Z were 
associated with a long-term (30 months after the first round 
MDA-Z) increase in both the prevalence of azithromycin-resis-
tant and inducible macrolide lincosamides and streptogramin B 
(MLSB)–resistant S. aureus [16]. In Papua New Guinea, the 
proportion of azithromycin-resistant S. aureus was 5 times 
higher among pregnant women treated with azithromycin than 
in those in the control group [17].  
In a recent trial in The Gambia, administering 2 g of oral 
azithromycin during labor reduced significantly maternal and 
neonatal nasopharyngeal carriage of S. pneumoniae, S. aureus, 
and group B Streptococcus [6], as well as maternal and neona-
tal infections [18, 19]. Four weeks after birth, children in the 
intervention arm had similar prevalence of nasopharyngeal 
carriage of S. pneumoniae azithromycin resistance compared to 
those in the control arm (2.1% vs 2.2%; P = 1.000), but higher 
prevalence of S. aureus azithromycin resistance (4.5% vs 
16.7%; P < .001) [20]. To determine the persistence of 
azithromycin resistance among study children, we collected 
nasopharyngeal swabs (NPSs) at their first birthday. 
 
MATERIALS AND METHODS 
 
Study Site and Population  
Trial participants were recruited from the Bundung Maternal 
and Child Health Hospital, formerly called Jammeh Foundation 
for Peace, a government-run health center located in western 
Gambia that manages on average 4500 deliveries per year [21]. 
The population covers the main ethnic groups in The Gambia 
with a high illiteracy rate. The climate of the area is typical of 
the sub-Sahel region. 
 
Main Trial  
Details of the study protocol have been described elsewhere 
[21]. In brief, this was a phase 3, double-blind, placebo-con-
trolled trial where 829 pregnant women attending the labor 
ward in the study health facility were randomized to receive a 
single oral dose of 2 g of either oral azithromycin or placebo 
(ratio 1:1). The trial started in April 2013 and lasted 14 months 
(12-month recruitment period and 2 additional months of 
follow-up). Study participants (women and their newborns) 
were monitored for 8 weeks after the intervention. Neonatal 
NPSs were collected during the first 4 weeks of the follow-up 
 
as part of the trial. Prevalence of nasopharyngeal carriage of S. 
pneumoniae was significantly lower during the entire neo-natal 
period among neonates exposed to azithromycin (at day  
28: 37.2% vs 24.8%; prevalence ratio [PR], 0.67 [95% confi-dence 
interval {CI}, .53–.83]; P < .001). Prevalence of carriage of S. 
pneumoniae–resistant strains was low throughout and sim-ilar 
between arms (at day 28: 2.1% vs 2.2%; PR, 1.04 [95% CI, 
 
.40–2.75]; P = 1.000). For S. aureus, prevalence of nasopharyn-
geal carriage peaked at day 6 and by day 28 was still 
significantly lower in the azithromycin arm (35.3% vs 25.6%; 
PR, 0.73 [95% CI, .58–.91]; P = .005), whereas prevalence of 
azithromycin-re-sistant S. aureus carriage peaked at day 28 
(4.5% vs 16.7% in the azithromycin and placebo arms; PR, 3.68 
[95% CI, 2.19–2.75]; P < .001) [20]. 
 
Cross-sectional Survey  
Between November 2014 and May 2015, children aged 12 
months (range, 11–13 months) whose mother had partic-ipated 
in the main trial were visited at home and had an NPS collected. 
Consent was obtained by a trained nurse blinded to the 
treatment allocation. 
 
Ethical Approval  
Both the main trial and the cross-sectional survey (CSS) were 
approved by the Joint Medical Research Council/The Gambia 
Government Ethics Committee. Mothers of children included 
in the CSS signed an additional informed consent. 
 
Sample Handling  
The NPS was collected using calcium alginate (Expotech USA) 
swab as described previously [21]. In brief, each swab was 
immediately placed into a vial containing skim milk-tryp-tone-
glucose-glycerol transport medium and then into a cold box 
before being transported to the laboratory within 8 hours [22]. 
Upon receipt, the tubes were vortexed for a minimum of 20 
seconds before being stored in freezers at –70°C. 
 
Laboratory Methods  
Details of the laboratory methods were described previously 
[21]. In brief, 50 μL of the sample was dispensed onto genta-
micin blood agar (GBA) (CM0331 Oxoid, United Kingdom, 
plus 5% sheep blood) and mannitol salt agar (MSA) (CM0085 
Oxoid, United Kingdom) for selective isolation of S. pneumo-
niae and S. aureus, respectively. 
 
Streptococcus pneumoniae  
After 20–24 hours of incubation at 37°C with 5% carbon diox-
ide, GBA plates were examined for typical α-hemolytic col-
onies. Morphologically distinct α-hemolytic colonies were 
selected and subcultured on another blood agar to obtain pure 
growth and screened for optochin susceptibility [22]. 
Streptococcus pneumoniae isolates were confirmed as 
described previously [21]. 
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Staphylococcus aureus  
Following 48 hours of incubation at 37°C, MSA plates were exam-ined 
for typical staphylococci colonies. Pale to golden yellow dome-shaped 
colonies 1–2 mm in diameter were cultured onto blood agar to obtain 
pure growth. A coagulase test was performed on all suspected colonies 
using the Staphaurex plus kit (Oxoid, United Kingdom, catalog number 
OXR30950201). Isolates testing positive for coagulase were confirmed 
to be S. aureus. 
 
Antibiotic Susceptibility Testing  
Antibiotic susceptibility was performed as described previously 
[21]. In brief, resistance was initially screened by disk diffusion 
method. Both S. pneumoniae and S. aureus isolates were screened 
using the following antibiotic discs: azithromycin (15 μg), chlo-
ramphenicol (30 μg), clindamycin (2 μg), and erythromycin (15 
μg). In addition, only S. pneumoniae isolates were screened for 
trimethoprim-sulfamethoxazole (1.25/23.75 μg) and oxa-cillin (1 
μg), and S. aureus isolates were screened for cefoxitin (30 μg). All 
isolates that were of intermediate or resistant by the disk diffusion 
method were further tested using the Etest for confirmation except 
those isolates resistant to cotrimoxazole. Due to limited resources, 
only 90 of these isolates were ran-domly selected to be confirmed 
by the Etest. Susceptibility to the different antibiotics was 
determined following the Clinical and Laboratory Standards 
Institute guidelines [23]. In addition, D-test was performed on all 
macrolide (azithromycin and/ or erythromycin)–resistant 
clindamycin-sensitive isolates to assess inducible clindamycin 
resistance [24]. In an additional effort to confirm resistance, all S. 
pneumoniae isolates found to be resistant by Etest to azithromycin, 
erythromycin, or clinda-mycin were retested using the VITEK-2 




Table 1.  Comparison of Children in the 12-Month Survey With 
Those Who Did Not Participate  
 
Variable  12-Month Survey, no./No. (%) P Value 
      
   Included Not Included  
       
Sex       
  Female 230/465 (49.5) 175/378 (46.3) .360 
  Male 235/465 (50.5) 203/378 (53.7)  
Ethnicity       
  Mandinka 201/462 (43.5) 151/361 (41.8) .367 
  Wollof 49/462 (10.6) 45/361 (12.5)  
  Jola 80/462 (17.3) 47/361 (13.0)  
  Fula 76/462 (16.5) 68/361 (18.8)  
  Other 56/462 (12.1) 50/361 (13.9)  
Maternal age at delivery, y     
  18–19 30/465 (6.5) 37/378 (9.8) .109 
  20–29 295/465 (63.4) 244/378 (64.6)  
  ≥30 140/465 (30.1) 97/378 (25.7)  
Multiple pregnancies       
  No 453/465 (97.4) 362/372 (95.8) .183 
  Yes 12/465 (2.6) 16/378 (4.2)  
         
 
Data Management and Statistical Analysis  
Laboratory data were transcribed onto bar-coded forms and 
submitted to data management for entry. The data were double 
entered in OpenClinica (www.openclinica.com), and antibiotic 
susceptibility data for S. pneumoniae were stored in a REDcap 
database.  
For each antibiotic, the resistant bacterial carriage preva-
lence was compared between trial arms using the χ
2
 test. This 
was done for both S. pneumoniae and S. aureus. In addition, we 
assessed if resistance up to day 28 posttreatment was associated 
with resistance 12 months later. For this analysis, only children 
who were sampled during all 5 time points in the trial (days 0, 
3, 6, 14, and 28) and were also sampled in the 12-month CSS 





Study Population  
Among 814 study children alive at the end of the initial trial period 
(8 weeks of age), 5 had died and 196 were >13 months at the time 
of the CSS survey. Among the remaining 613 children, 465 
(76.0%) were enrolled in this study and NPSs were collected from 
461 of them (99.1%). Demographic characteristics were similar 
between children included in the CSS and those who were not 
(Table 1). Baseline characteristics (sex, ethnic group, season at 
birth, maternal age, and age at follow-up) in the azi-thromycin (n 
= 226) and the placebo groups (n = 235) were similar, except for a 
higher number of multiple pregnancies in the placebo arm (P = 
.037; Table 2). 
 
Prevalence of Bacterial Carriage  
The prevalence of S. pneumoniae carriage was high and similar 
between arms (85.0% vs 82.1% in the azithromycin and placebo 
arms, respectively; odds ratio [OR], 1.23 [95% CI, .73–2.08]; 
Table 3). The prevalence of S. aureus carriage was lower but also 
similar between arms (21.7% vs 21.3% in the azithromycin and 
placebo arms respectively; OR, 1.02 [95% CI, .64–1.64]). 
 
Prevalence of Antibiotic Resistance  
Streptococcus pneumoniae  
Only 6 of the 385 S. pneumoniae isolates were resistant to azith-
romycin, and prevalence was similar between study arms (1.8% vs 
0.9% in the azithromycin and placebo arms, respectively; OR, 2.10 
[95% CI, .30–23.38]). Prevalence of S. pneumoniae resistance 
against the other antibiotics tested was also similar between arms 
(Table 4). D-test was performed on 14 samples (6 azithromycin and 
8 erythromycin resistant) and all were nega-tive. Resistance to 
cotrimoxazole based on disk diffusion was the highest among all 
the antibiotics tested (Table 4). Among the cotrimoxazole-resistant 
isolates, 30% were retested using Etest and 63.3% (57 of 90) were 
confirmed. All S. pneumoniae isolates were susceptible to at least 
3 of the antibiotics tested, 
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Table 2.  Baseline Characteristics of Mothers and Children in the 2 Groups  
 
   Azithromycin Group Placebo Group  
Characteristic (n = 226) (n = 235) P Value 
      
Maternal age at delivery, mean (SD) 26.5 (5.3)
a 
26.6 (5.0) .684 
Mode of delivery      
  Vaginal 220 (97.4) 233 (99.2) .165 
  Cesarean 6 (2.7) 2 (0.9)  
Information at birth      
  Multiple pregnancy 2 (0.9) 10 (4.3) .037 
  Sex
b      
    Female 117 (51.8) 104 (44.3) .266 
    Male 107 (47.4) 124 (52.8)  
Ethnicityc      
  Mandinka 93 (41.2) 106 (45.1) .490 
  Jola 44 (19.5) 36 (15.3)  
  Wollof 26 (11.5) 23 (9.8)  
  Fula 37 (16.4) 38 (16.2)  
  Others 24 (10.6) 31 (13.2)  
Season      
  Dry 178 (78.8) 188 (80.0) .909 
  Wet 48 (21.2) 47 (20.0)  
Child age at follow-up visit, mean (SD) 12.24 (0.6) 12.27 (0.6) .486 
          
Data are presented as No. (%) unless otherwise indicated.  
Abbreviation: SD, standard deviation.  
aThree missing data in the azithromycin arm.  
bNine missing data (2 in the azithromycin arm and 7 in the placebo arm).  
cThree missing data (2 in the azithromycin arm and 1 in the placebo arm).  
 
except for 1 isolate in the azithromycin arm that was susceptible 
to only 2 antibiotics (Figure 1). 
 
Staphylococcus aureus  
Overall, 13 of the 99 S. aureus isolates were resistant to azithro-
mycin, and prevalence was similar between study arms (3.1% vs 
2.6% in the azithromycin and placebo arms, respectively; OR, 1.22 
[95% CI, .35–4.47]). Prevalence of S. aureus resis-tance against 
the other antibiotics was low (<3.0%) and similar between arms 
(Table 4). All S. aureus isolates from both arms were susceptible 
to at least 1 of the antibiotics tested (Figure 2). 
 
Association of Azithromycin Resistance up to 28 Days and 1 
Year Posttreatment (CSS)  
There were 427 participants with complete information on S. 
pneumoniae and S. aureus resistance (samples at the 5 time 
 
 
points during the neonatal period and at 1 year posttreatment). For 
S. pneumoniae, 0.73% of the participants not carrying a resistance 
strain during the neonatal period had a resistant strain 1 year after 
birth; prevalence of resistant strains was sig-nificantly higher 
(14.3%) in those carrying a resistant strain during the neonatal 
period (P < .001). For S. aureus, prevalence of resistant strains at 
1 year was not associated with carriage during the neonatal period 




Twelve months after administering azithromycin to women in 
labor, the prevalence of S. aureus azithromycin resistance pre-
viously observed during the neonatal period had returned to 
baseline levels, with no differences between study arms. This 
was also true for S. pneumoniae azithromycin resistance. 
 
 
Table 3.  Univariate Analysis of Bacterial Carriage by Arm After 12 Months  
 
Bacteria Azithromycin (n = 226), No. (%) Placebo (n = 235), No. (%) OR (95% CI) P Value 
       
Streptococcus pneumoniae       
  Yes 192 (85.0) 193 (82.1) 1.23 (.73–2.08) .413 
  No 34 (15.0) 42 (17.9)    
Staphylococcus aureus       
  Yes 49 (21.7) 50 (21.3) 1.02 (.64–1.64) .916 
   No 177 (78.3) 185 (78.7)    
           
Abbreviations: CI, confidence interval; OR, odds ratio.  
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Table 4.  Prevalence of Antibiotic-Resistant Bacteria, by Arm, After 12 Months  
 
Bacteria and Antibiotic  Azithromycin (n = 226), No. (%) Placebo (n = 235), No. (%) OR (95% CI) P Value 
         
Streptococcus pneumoniae         
  Azithromycin
R 
Yes 4 (1.8) 2 (0.9) 2.10 (.30–23.38) .384 
  No 222 (98.2) 233 (99.1)    
  Erythromycin
R 
Yes 5 (2.2) 3 (1.3) 1.75 (.34–11.38) .442 
  No 221 (97.8) 232 (98.7)    
  Chloramphenicol
R 
Yes 8 (3.5) 3 (1.3) 2.84 (.67–16.78) .111 
  No 218 (96.5) 232 (98.7)    
  Penicillin
R 
Yes 0 (0.0) 0 (0.0) NA   
  No 226 (100.0) 235 (100.0)    
  Clindamycin
R 
Yes 1 (0.4) 0 (0.0) NA  .307 
  No 225 (99.6) 235 (100.0)    
  Cotrimoxazole
R,a 
Yes 140 (92.1) 152 (93.3) 0.84 (.33–2.17) .696 
  No 12 (7.9) 11 (6.8)    
Staphylococcus aureus         
  Azithromycin
R,b 
Yes 7 (3.1) 6 (2.6) 1.22 (.35–4.47) .724 
  No 219 (96.9) 229 (97.5)    
  Erythromycin
R,b 
Yes 5 (2.2) 5 (2.1) 1.04 (.24–4.59) .950 
  No 221 (97.8) 230 (97.9)    
  Cefoxitin
R 
Yes 0 (0.0) 2 (0.9) NA (.00–1.99) .165 
  No 226 (100.0) 233 (99.2)    
  Chloramphenicol
R 
Yes 1 (0.4) 3 (1.3) 0.34 (.01–4.32) .334 
  No 225 (99.6) 232 (98.7)    
  Clindamycin
R 
Yes 6 (2.6) 7 (3.0) 0.89 (.24–3.14) .834 
  No 220 (97.4) 228 (97.0)    
            
Testing was done with Etest and VITEK-2.  
Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio; R, resistant.  
aOnly 63.3% (57/90) of cotrimoxazole-resistant S. pneumoniae isolates by disk diffusion were confirmed by Etest.  
bIsolates of intermediate azithromycin (4 µg/mL) or erythromycin (1–4 µg/mL) resistance were considered sensitive.  
 
Prevalence of azithromycin-resistant pneumococcal carriage was 
low among infants from both groups. This was expected as 
prevalence of resistance was low and similar between trial arms 
during the 4 weeks following the intervention [20]. Our results are 
similar to those of the Gambian trachoma trial in which chil-dren 
received an annual dose of azithromycin for 1 or 3 years [9] 
 
 
and prevalence of S. pneumoniae azithromycin resistance was 
similar between arms 6 months after dose 3. They are also con-
sistent with the trial conducted in northern Tanzania, where no 
association of prevalence of macrolide-resistant S. pneumoniae 
was found 6 months following MDA-Z [25]. Nevertheless, in some 
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Figure 1.  Heat map showing pattern of Streptococcus pneumoniae isolates resistant (R) to at least 1 antibiotic (except cotrimoxazole), by 
arm. Resistance Etest cutoff values: azithromycin, ≥2 μg/mL; penicillin, ≥8 μg/mL; chloramphenicol, ≥8 μg/mL; erythromycin, ≥1 μg/mL; and 
clindamycin, ≥1 μg/mL. *Cotrimoxazole susceptibility patterns for isolates resistant to at least 1 of azithromycin, penicillin, chloramphenicol, 
erythromycin, and clindamycin are included in the table. Resistance cutoff value was ≤18 mm using disk diffusion.  
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Figure 2.  Heat map showing pattern of Staphylococcus aureus isolates resistant (R) to at least 1 antibiotic, by arm. Resistance Etest cutoff 
values: azithromycin, ≥8 μg/ mL; chloramphenicol, ≥32 μg/mL; erythromycin, ≥16 μg/mL; clindamycin, ≥4 μg/mL; cefoxitin for methicillin-
resistant Staphylococcus aureus (MRSA), ≥8. Intermediate Etest cutoff values: azithromycin, 4 μg/mL; erythromycin, 1–4 μg/mL.  
 
Ethiopia, prevalence of azithromycin-resistant S. pneumoniae 
increased after 4 rounds of MDA-Z for trachoma control and did 
not return to baseline 12 months after the last round [14]. This 
is probably due to the higher prevalence of resistance at baseline 
(9.2%) [14] as compared to The Gambia (1.4%) [20] and 
Tanzania (0%) [25], and to the larger number of MDA-Z rounds. 
Indeed, frequent exposure to treatment and higher resistance at 
baseline are associated with increased prevalence of macrolide 
resistance that persists for a very long time [26].  
Only 1 isolate (from the azithromycin arm) showed resis-
tance to both macrolides and clindamycin, suggesting consti-
tutive resistance. All clindamycin-sensitive, macrolide-
resistant isolates had a negative D-test, indicating no evidence 
of induc-ible resistance. Macrolide exposure could potentially 
induce clindamycin resistance through methylation of the 
common ribosomal binding site for macrolides, clindamycin as 
well as streptogramin B (MLSB), often referred to as the MLSB 
pheno-type [27]. However, in our study population, macrolide 
expo-sure did not induce resistance to clindamycin.  
For cotrimoxazole, two-thirds of the S. pneumoniae isolates 
resistant by disk diffusion were confirmed by Etest and, there-fore, 
actual resistance was probably around 60%. Such high prevalence 
among the children has been previously described [28] and is 
probably the result of high cotrimoxazole use in The Gambia; no 
increase as a result of the intervention was observed. 
 
Nearly all S. aureus isolates resistant to azithromycin were 
resistant to erythromycin and approximately two-thirds were also 
resistant to clindamycin, suggesting that the underlying mechanism 
was constitutive, mediated by the erm gene [27]. There were 2 
cases of methicillin-resistant S. aureus (MRSA) in the study, both 
in children from the placebo arm, and therefore 
 
 
not associated with the intervention. To our knowledge, this is the 
first time MRSA has been reported from carriage in The Gambia, 
although it was previously reported from invasive isolates [29]. 
 
This study had some limitations. One is the lack of informa-
tion between the last sample collection in the main trial and the 
survey done at the infants’ first birthday. We were unable to 
determine how long S. aureus–resistant isolates persisted. Such 
information is important to determine the potential risk of 
resistance transmission and establishment within the pop-
ulation. Despite the lack of information on antibiotic use by the 
study participants between 2 and 12 months of age, we did not 
expect major differences between trial arms, as this was a 
randomized trial. The survey carried out at about 12 months 
postintervention was able to include about two-thirds of study 
participants, which is a substantial proportion of the study pop-
ulation; we did not observe significant differences between chil-
dren included in the survey and those left out. Exposure to a 
macrolide in our study population may have also resulted in the 
emergence of macrolide-resistant, gram-negative bacteria. In 
Tanzania, rectal swabs collected from young children following 
MDA-Z exposure were significantly associated with higher azi-
thromycin-resistant Escherichia coli carriage at 1 month post-
MDA (OR, 15.27; P < .001) and all subsequent surveys [30]. 
Our analysis was based on gram-positive bacteria as we only 
collected NPS.  
In conclusion, administering 2 g of azithromycin to Gambian 
women in labor induced a transient azithromycin resistance in S. 
aureus that lasted <12 months. Although the long-term impact on 
prevalence of resistance of the 2 bacteria is reassur-ing, 
pathogenicity and transmissibility of resistant S. aureus strains 
observed in the short term warrant further investigation. 
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Background: Oral azithromycin given during labour reduces carriage of bacteria responsible for neonatal sepsis, 
including Staphylococcus aureus. However, there is concern that this may promote drug resistance. 
 
Objectives: Here, we combine genomic and epidemiological data on S. aureus isolated from mothers and babies 
in a randomized intra-partum azithromycin trial (PregnAnZI) to describe bacterial population dynamics and re-
sistance mechanisms. 
 
Methods: Participants from both arms of the trial, who carried S. aureus in day 3 and day 28 samples post-
intervention, were included. Sixty-six S. aureus isolates (from 7 mothers and 10 babies) underwent comparative 
genome analyses and the data were then combined with epidemiological data. Trial registration (main trial): 
ClinicalTrials.gov Identifier NCT01800942. 
 
Results: Seven S. aureus STs were identified, with ST5 dominant (n=40, 61.0%), followed by ST15 (n=11, 17.0%). ST5 
predominated in the placebo arm (73.0% versus 49.0%, P=0.039) and ST15 in the azithromycin arm (27.0% versus 
6.0%, P=0.022). In azithromycin-resistant isolates, msr(A) was the main macrolide resistance gene (n=36, 80%). Ten 
study participants, from both trial arms, acquired azithromycin-resistant S. aureus after initially har-bouring a susceptible 
isolate. In nine (90%) of these cases, the acquired clone was an msr(A)-containing ST5 S. aureus. Long-read 
sequencing demonstrated that in ST5, msr(A) was found on an MDR plasmid. 
 
Conclusions: Our data reveal in this Gambian population the presence of a dominant clone of S. aureus harbour-
ing plasmid-encoded azithromycin resistance, which was acquired by participants in both arms of the study. 
Understanding these resistance dynamics is crucial to defining the public health drug resistance impacts of 






Azithromycin, a second-generation broad-spectrum macrolide, is 
used to treat infections such as pneumonia, middle ear infections and 
sexually transmitted infections.1,2 It has also been used in mass drug 
administration (MDA) campaigns to control trachoma in several 
endemic countries in Africa.3–5 The impact of these MDA campaigns 
has varied from one country to another.6–8 MDA with azithromycin 




trachoma control, having been shown to reduce asymptomatic 
pneumococcal carriage for at least 1 month,9 and all-cause mor-
tality in children.10,11 However, a concern is that MDA-Z has been 
associated with an increase in the prevalence of macrolide-
resistant bacterial species, even after the administration of only a 
single dose.12 The spread of these resistant bacterial populations 
and the associated risk to regions that may implement MDA-Z are 
not fully understood. 
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This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ 
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Staphylococcus aureus is regularly implicated as a species in 
which azithromycin resistance emerges following MDA-Z cam-
paigns. In Papua New Guinea, the proportion of azithromycin-
resistant (azithromycinR) S. aureus was five times higher among 
pregnant women treated with azithromycin than in those in the control 
group.13 A study in rural Gambia showed that three annual rounds of 
MDA-Z were associated with a long-term increase in the prevalence 
of azithromycinR S. aureus. There are three recognized types of 
acquired macrolide resistance mechanisms in S. aureus:  
(i) methylation of the ribosomal target (erm gene);14,15 (ii) active 
efflux [msr(A) gene];14,16,17 and (iii) inactivation of the macrolide 
(mph/ere gene).18,19 In the absence of these genes, mutations in 
ribosomal proteins have been implicated in macrolide 
resistance.20 As azithromycin is a synthetic analogue of 
erythromycin, it is presumed that these resistance mechanisms 
are active against both antimicrobials. However, molecular data 
confirming this association are limited for azithromycin, in 
particular for the efflux mechanism encoded by msr(A). Further, 
there are limited data available on the distribution of these 
macrolide resistance-encoding genes following public health 
interventions using azithromycin.  
A recent MDA-Z trial in The Gambia, the Prevention of Bacterial 
Infections in Newborn (PregnAnZI) trial, a double-blinded placebo-
controlled trial in which oral intra-partum azithromycin (2 g) was 
administered, showed that phenotypic resistance to azithromycin was 
associated with S. aureus isolates harbouring msr(A) or erm(C) 
genes.21 Public health interventions using antibiotics, in addition to 
driving the emergence of resistance, may also greatly alter the local 
molecular epidemiology of S. aureus. The distribution of dom-inant 
MSSA clones in Africa is heterogeneous,22 and in The Gambia there 
is currently a paucity of data on the prevalence of S. aureus STs, 
although ST15 and ST5 have been most commonly reported.23,24 
The ST15 lineage in Africa has been reported to fre-quently harbour 
genes encoding the Panton–Valentine leucocidin (PVL) toxin 
(25.9%–90.0%) and enterotoxin A (22.0%–74.6%), sug-gesting a 
potential for increased virulence in this lineage.22 
The recent PregnAnZI trial was undertaken to assess the effi-
cacy of one oral dose of azithromycin administered to women dur-
ing labour in lowering bacterial carriage both in the mother and in 
her newborn as a necessary step to reduce puerperal and 
neonatal sepsis. The trial revealed that azithromycin treatment 
significantly decreased carriage of S. aureus, group B 
Streptococcus and Streptococcus pneumoniae, but increased the 
prevalence of azithromycinR S. aureus, amongst the population 
of bacterial isolates recovered during a 28 day follow-up period.12 
However, carriage of the latter was observed to wane in babies 
12 months after delivery.25  
The primary aims of this study were to: (i) use genomics to char-
acterize the population of azithromycinR S. aureus recovered from 
mothers and babies during a 28 day follow-up period; (ii) identify the 
genetic mechanisms responsible for azithromycin resistance in this 
population and their genetic context; and (iii) explore the potential 
roles of clonal replacement and transmission of azithromycinR S. 





The PregnAnZI trial was a Phase III, double-blind, placebo-controlled trial 
where 829 pregnant women attending the labour ward received a single oral 
dose (2 g) of azithromycin or placebo (ratio 1:1). The study protocol has been 
described elsewhere.26 Participants were monitored for 8 weeks and 
nasopharyngeal swabs were collected during the first 4 weeks of the follow-up 
(day 0 for mothers and days 3, 6, 14 and 28 for mothers and babies).  




The trial was approved by the Joint MRC/Gambia Government Ethics 
Committee. Mothers of children signed informed consent. 
 
Sample selection  
To explore potential genetic diversity amongst azithromycinR S. aureus, we 
stratified isolates collected at day 3 and day 28 into four groups (Figure 1). Two 
groups were participants in the azithromycin treatment arm where an 
azithromycinR S. aureus was recovered at both timepoints (group 1) or only at 
day 28, with an azithromycin-susceptible (azithromycinS) S. aureus iden-tified 
at day 3 (group 3). The other two groups represented the same micro-biological 
division, but for samples recovered from participants assigned to the placebo 
arm [azithromycinR S. aureus at day 3 and day 28 (group 2) or azithromycinS 
S. aureus at day 3 and azithromycinR S. aureus at day 28 (group 4)]. A total of 
17 participants (34 isolates) were selected from these four groups. In addition, 
all S. aureus recovered from the above subjects at other timepoints (days 0, 6 
and 14) were included. 
 
WGS and bioinformatic analyses 
 
WGS was performed on the NextSeq 500 (Illumina) using 2%150 bp chem-
istry. One isolate (S80062MN28) was subjected to long-read sequencing on 
the RS-II (Pacific Biosciences). Bioinformatic approaches and analyses 
included assembly, annotation and comparative genomics. The global S. 
aureus phylogeny was inferred using publicly available genomes. Antibiotic 
resistance and virulence gene detection was performed using the NCBI 
antimicrobial resistance database (ncbi: updated 20 September 2018) and the 
virulence factor database (vfdb: updated 14 August 2018). All se-quence data 
generated for this study have been made publicly available through the 
European Nucleotide Archive, project accession PRJEB31151. 
 
Cloning and transformation of erm(C) and msr(A) genes 
 
An empty vector control and a vector containing erm(C) or msr(A) were 
electroporated into an ST5 azithromycinS S. aureus strain 
(S70065MN00). Colonies were screened to confirm the presence of either 




Duplicate conjugation experiments were performed using an 
azithromycin-resistant donor strain (S80062MN28) and an azithromycin-
susceptible re-cipient strain (S70065MN00). Resistance profiles of donor, 
recipient and transconjugants are described in Table S1. 
 
Antimicrobial susceptibility testing 
 
Phenotypic susceptibility to azithromycin and erythromycin was deter-
mined using Etest (bioMe´rieux), performed as per the manufacturer’s 
recommendations. 
 
Patients and methods 
 
Additional Materials and methods are provided in the Supplementary 




Fisher’s exact test was used to compare the prevalence of STs or macrolide 
resistance genes between the azithromycin and placebo groups. A P value  










          Study participants        
                        
                       
                        
 Azithromycin arm        Placebo arm 
 414 Women (49.9%)       415 Women (50.1%) 
 419 Babies (49.7%)        424 Babies (50.3%) 
                      
               
At least 1 NPS positive for S. aureus    At least 1 NPS positive for S. aureus 
                     
                        
 149 Women (36.0%)       216 Women (52.0%) 
 173 Babies (41.3%)        320 Babies (75.5%) 
                      
               
S. aureus positive at day 3 + day 28    S. aureus positive at day 3 + day 28 
                     
                        
 79 Women (19.1%)       152 Women (36.6%) 
 147 Babies (35.1%)        271 Babies (63.9%) 
                      
                     
                        
AZM
R
 day 3    AZMS day 3     AZMR day 3    AZMS day 3 
AZM
R
 day 28    AZM
R
 day 28     AZM
R
 day 28    AZM
R
 day 28 
Group 1    Group 3      Group 2     Group 4 
                      
                    
65 Women (15.7%)  1 Woman (0.2%)   18 Women (4.3%)  2 Women (0.5%) 
101 Babies (24.1%)  3 Babies (0.7%)   43 Babies (10.1%)   4 Babies (0.9%) 
                     
                
Random selection  All samples   Random selection  Random selection 
                    
                        
2 Women 3 Babies  1 Woman 3 Babies   2 Women 2 Babies  2 Women 2 Babies 
 n=10    n=8    n=8    n=8 








Woman or Baby from above if positive for S. aureus at any  




Total number of S. aureus  
n=66 
 
Figure 1. Flow chart showing the sample selection criteria from women and babies in the PregnAnZI trial. NPS, nasopharyngeal swab; AZMR, 
azithro-mycin resistant; AZMS, azithromycin susceptible. Resistance Etest cut-off values: azithromycin 8 mg/L. 
 
 
of 0.05 was used as the cut-off for statistical significance. All analyses 
were done using STATA/SE v12.1 (https://www.stata.com/). 
 
Results and discussion 
 
Genomic characterization of the study population 
 
A total of 66 S. aureus isolates recovered from 7 mothers and 10 
babies were included in this study. Of the 66 isolates, half (n=33) were 
recovered from the nine participants selected from the azithromycin-
treatment arm and the other half from the eight participants selected 
from the placebo arm of the PregnAnZI trial.  
 
 
In silico MLST of the 66 S. aureus isolates revealed seven different 
STs: ST1 [and a novel ST1 single-locus variant (ST1-SLV)], ST5, 
ST8, ST15, ST152 and ST669 (Table 1). Overall ST5 was the 
dominant ST, representing 61.0% of isolates (n=40) recovered from 
14 partic-ipants, followed by ST15, representing 17.0% of isolates 
(n=11) recovered from 7 participants. The prevalence of ST5 was 
higher in the placebo arm (73.0% versus 49.0%, P=0.039), while the 
preva-lence of ST15 was higher in the azithromycin treatment arm 
(27.0% versus 6.0%, P=0.022). These finding are largely consistent 
with previous molecular epidemiological data from The Gambia, in 
which ST15 and ST5 were common STs identified in cases of both 









Table 1. Distribution of STs and macrolide resistance amongst the study population  
 
   All samples   Azithromycin treatment arm Placebo treatment arm 
          
MLST  all AZMR all AZMR all AZMR 
ST5 14 (40) 14 (36) 6 (16) 6 (16)  8 (24) 8 (20) 
ST15 7 (11) 1 (1)  5 (9) 1 (1)  2 (2) 0 (0) 
ST1 1 (4) 0 (0)  – – 1 (4) 0 (0) 
ST669 1 (4) 1 (4)  1 (4) 1 (4)  – – 
ST8 1 (3) 0 (0)  – – 1 (3) 0 (0) 
ST152 1 (3) 1 (3)  1 (3) 1 (3)  – – 
ST1-SLV 1 (1) 1 (1)  1 (1) 1 (1)  – – 
          
AZMR, azithromycin resistant.         
Data are shown as number of participants (number of isolates).     
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Figure 2. Distribution and phylogenetic relatedness of participant isolates. Illustrated are ML phylogenetic trees for each ST identified in the study 
population (excluding the ST1-SLV), inferred from whole-genome alignments. Branch tips are coloured based on phenotypic susceptibility to azithro-
mycin (blue=susceptible and red=resistant, as determined by Etest). Scale bar indicates the estimated substitutions per site. Isolates recovered from 
the same participant are indicated by a larger circle, labelled with the participant ID and coloured based on the treatment arm to which the partici-pant 
was assigned (purple=azithromycin and green=placebo). Participants with isolates representing multi-STs are connected by a dotted line. Isolates 
belonging to ST1 and ST152 were found to harbour the PVL toxin-encoding gene, lukFS. 
 
 
colonization and disease.23,24 Unlike previous reports of 
increasing PVL positivity in the Gambian ST15 population,22 the 
lukFS genes were only identified in the isolates representing ST1 
and ST152 (Figure 2).  
To explore the genetic relationships between isolates, a max-imum 
likelihood (ML) phylogenetic tree was inferred for each ST (excluding the 
ST1-SLV). In the case of ST1, ST8, ST152 and ST669, each clone was 
recovered from a single participant and demon-strated limited core SNP 
diversity (Figure 2). This finding suggested  
 
 
that these participants maintained the same S. aureus clone over the 
28 day follow-up period. Only ST5 and ST15 were recovered from 
multiple participants (n=14 and 7, respectively) and as a group 
demonstrated core SNP diversity. Isolates of the same ST recovered 
from the same participant, however, largely formed a single, 
genetically distinct clade within both phylogenetic trees (Figure 2). 
The median pairwise core SNP distance between isolates recovered 
from the same participant was 2.5 (±16.4, range 0–85) for ST5 and 
104 (±61.2, range 0–125) for ST15; for isolates 
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Figure 3. Individual participant timelines. Illustrated are the isolate timelines for each participant selected for the study, grouped based on the selec-
tion criteria outlined in Figure 1. Each participant is indicated by their participant ID and the adjacent circles represent the isolates recovered from 
samples taken prior to the intervention (day 0 for mothers) and following the intervention on days 3, 6, 14 and 28 (for mothers and babies). Isolate 
circles are coloured based on the phenotypic susceptibility to azithromycin (blue=susceptible and red=resistant, as determined by Etest). The internal 
number indicates the in silico MLST of the isolate and the superscript letter indicates the macrolide resistance gene detected, ‘m’ for msr(A) and ‘e’ for 
erm(C). Black lines connecting adjacent isolates indicate that the same clone has probably been maintained, with the pairwise core SNP distance pro-
vided. Alternatively, gaps between adjacent isolates indicate a potential clonal replacement event. AZMR, azithromycin resistant; AZMS, azithromycin 
susceptible. 
 
recovered from different participants it was 95 (±34.2, range 0–200) for 
ST5 and 115 (±24.1, range 9–136) for ST15. A potential clonal re-
placement event probably occurred in one participant (P046/9), with the 
ST5 MSSA isolate recovered on day 3 having a pairwise core SNP 
distance of 84 and 85 to the ST5 MSSA isolates recovered on day 6 and 
28, respectively (Figure 3, Dataset S3). Another two partic-ipants (P027/0 
and P0361/2) appeared to be involved in a potential transmission event 
as the four ST5 MSSA isolates recovered from these participants 
demonstrated a pairwise core SNP distance of 3 (Dataset S3). There was 
no apparent clustering of participant iso-lates based on the treatment 
received (Figure 2). 
 
Genetic basis of azithromycin resistance  
Of the 66 S. aureus isolates, 21 were phenotypically azithromycinS 
and 45 azithromycinR as determined by Etest. None of the 
azithromycinS S. aureus carried a known azithromycin resistance-
conferring gene, whereas all azithromycinR S. aureus were found to 
carry either an erm(C) (n=9, 20%) or msr(A) (n=36, 80%) gene 
(Figure 3), genes associated with macrolide resistance. Mutations in 
genes encoding ribosomal proteins (rplD, rplV and 23S rRNA)  
 
were investigated. Only two missense mutations were identified: RplD 
A133D and RplD T145I. Neither has been previously reported, and 
they were identified in four isolates carrying erm(C) (P471/8) and one 
isolate carrying msr(A) (P027/0), respectively.  
The two macrolide resistance genes are associated with different 
phenotypes: carriage of msr(A) among staphylococci is associated with 
phenotypic resistance to 14-membered (clarithromycin, dirith-romycin and 
erythromycin) or 15-membered (azithromycin) ring macrolides and 
streptogramin A, but susceptibility to 16-membered ring macrolides.18 
Carriage of erm genes in staphylococci is associ-ated with a broader 
phenotypic resistance depending on whether the gene is inducible or 
constitutively expressed. The former, often referred to as iMLSB, mediates 
resistance to 14- and 15-membered macrolides and streptogramin B, but 
susceptibility to 16-membered macrolides and lincosamides, with a risk of 
constitutive expression arising in vivo.18,27 The latter, denoted by cMLSB, 
mediates resistance to all macrolide, lincosamide and streptogramin B 
antibiotics.18  
The prevalence of each gene differed significantly when iso-lates 
were grouped based on the intervention which the partici-pant 
received (P=0.002). The erm(C) gene was carried by isolates 
belonging to ST15, ST152, ST669 and the ST1-SLV, and were only 

































Figure 4. Schematic for the structure of pS80062MN28. Illustrated is the structure of pS80062MN28 (central sequence PRJEB31151) with genes of 
interest annotated. pS800262MN28 has been aligned with S. aureus plasmid pJSA01 (accession AP014922.1) and S. epidermidis plasmid pSE95_1 
(ac-cession CP024438.1). Connecting lines indicate sequences that share >99% nucleotide sequence homology, coloured red or blue if the sequence 
was present in the same or reverse orientation, respectively. 
 
recovered from participants assigned to the azithromycin treat-ment 
arm. Conversely, the msr(A) gene was exclusively associated with 
ST5 MSSA isolates and was recovered from participants assigned to 
either treatment arm (Figure 3). As both resistance genes would 
provide protection against azithromycin, the factors mediating the 
differences in the prevalence of each gene between participants 
assigned to the different interventions are unclear. This finding 
requires confirmation in a larger isolate dataset. 
 
Genetic context of msr(A) 
 
In the ST5 lineage identified in this study, msr(A) was found to be 
located on an MDR staphylococcal plasmid (Figure 4). 
pS80062MN28 is 41069 bp in length and demonstrates significant 
similarity to the published S. aureus plasmid pJSA01 (accession 
AP014922.1) (Figure 4).28 Plasmid pJSA01 carries two virulence 
genes, a newly discovered enterotoxin (SE1) and the epidermal 
cell differentiation inhibitor A (EDIN-A) encoded by ednA.28,29 
Additionally, it carries genes encoding cadmium resistance 
(cadXD) and biocide tolerance (qacBR).28 Plasmid 
pS80062MN28 was found to carry both putative virulence genes 
and cadXD, but not qacBR, and contained a 12 kb region not 
present in pJSA01 (Figure 4). Approximately 9 kb of this region 
demonstrated signifi-cant similarity to a putative S. epidermidis 
plasmid pSE95_1 (acces-sion CP024438.1),30 and included 
msr(A) and the b-lactamase resistance-encoding gene blaZ 
(Figure 4). In all msr(A)-harbouring ST5 MSSA isolates, an 27 kb 
contig was identified, representing the plasmid region that spans 
from the ISSau6-type transposase upstream of cadXD to another 
copy upstream of SE1 (Figure 4), suggesting that all isolates 
probably carried a pS80062MN28-like plasmid.  
To demonstrate that msr(A) was responsible for macrolide re-
sistance in the ST5 lineage, a copy of the gene was transformed  
 
into a macrolide-susceptible ST5 isolate from the study collection 
(S70065MN00), using vector pRAB11.31 Two allelic variants of 
erm(C) [erm(C)_2 and erm(C)_13] were also tested. 
Transformation of an empty vector did not result in a change in 
azithromycin or erythromycin susceptibility in isolate 
S70065MN00; however, transformation of any one of the three re-
sistance genes resulted in an increase in the azithromycin MIC 
from 1.0 to >256 mg/L (Figure S1), the first time introduction of 
msr(A) or erm(C) genes in a previously azithromycinS S. aureus 
clinical isolate has been shown to result in azithromycin 
resistance. All clinical S. aureus isolates carrying either the 
erm(C) or msr(A) gene had similarly high MIC values as those 
shown in the cloning experiment (MIC 256 mg/L). The MIC values 
for all azithromycin-resistant and -susceptible isolates are 
included in Dataset S1 (col-umn F). WGS of transformants 
demonstrated no additional muta-tions potentially contributing to 
azithromycin resistance. Therefore, acquisition of msr(A), 
probably through uptake of the plasmid, is responsible for 
macrolide resistance in the ST5 lineage. Results of the bacterial 
conjugation experiment demonstrated that the transfer of the 
msr(A)-containing resistance plasmid was <1.06%10
#14 between 
S. aureus, indicating a low frequency of transmission. 
 
Contextualization of the study population 
 
To contextualize the Gambian isolates of this study with the global 
population of S. aureus, an ML phylogenetic tree comprising 7126 
publicly available S. aureus genomes together with the sequenced 
isolates of this study was constructed, as well as subtrees of CC5 and 
CC15 (Figure 5). The subtree of CC5 isolates (Figure 5b) illus-trated 
that the Gambian ST5 MSSA lineage identified in this study 
represented a single monophyletic clade, consistent with local ex-
pansion of this clone. The most closely related isolate to this clade 
































































Figure 5. Phylogenetic contextualization of study isolates. (a) Illustrated is an ML phylogenetic tree for a global population of 7192 S. aureus iso-lates. 
The Gambian isolates identified in this study are indicated by white circles located at the branch tips. (b) A subtree of CC5 isolates and (c) a subtree 
of CC15 isolates. In both subtrees, branches with <85% support (approximate likelihood ratio test) are labelled with a red circle. The Gambian isolates 
identified in this study are indicated by circles located at the branch tips, coloured based on phenotypic susceptibility to azithro-mycin (blue=susceptible 
and red=resistant, as determined by Etest). Adjacent to each subtree is a vertical line of circles indicating the countries from which the isolates were 
recovered (refer to key); the heatmap indicates the presence or absence of three macrolide resistance genes: erm(C) (1), msr(A) (2) and mph/ere (3). 
The scale bar indicates the estimated number of core genome substitutions.  









was recovered from the UK (435 SNPs). Given the distribution of 
macrolide resistance genes in this CC5 population (Figure 5b), there 
is no clear source for pS80062MN28 in the Gambian ST5 lineage. 
Therefore, it remains unclear if the MDA-Z trial promoted the ex-
pansion of this lineage (already carrying the plasmid) or provided the 
necessary selection pressure for plasmid uptake from a cur-rently 
unidentified source. The potential consequences of either 
evolutionary mechanism are greater than simply increasing the 
prevalence of azithromycin resistance in a region due to the co-
location of msr(A) with other resistance and virulence genes on the 
plasmid. Therefore, the impact of pS80062MN28 carriage for bac-
terial fitness and pathogenicity requires further investigation. 
 
 
S. aureus, favouring azithromycinR clones. When combined with 
widespread transmission, this could explain the high prevalence of 
the ST5 lineage if it additionally has a colonization advantage over 
other azithromycinR clones. The absence of this lineage in the babies 
sampled at 1 year post-intervention suggests that any col-onization 
advantage, if indeed present, is only advantageous in the presence 
of high azithromycin use. Without a snapshot of the mo-lecular 
epidemiology of S. aureus in the catchment area prior to the trial, 
limited conclusions can be drawn about the impact that the trial has 
had on the S. aureus population and highlights the need for such 
information prior to any subsequent MDA campaigns. 
 
Population dynamics of azithromycinR S. aureus carriage  
As all participants were sampled at multiple and consistent time-points 
following administration of either azithromycin or the pla-cebo, it 
presented an opportunity to explore the S. aureus population dynamics of 
each participant during the 28 day follow-up period. The isolate timelines 
are illustrated in Figure 3. Amongst the 17 par-ticipants, two common 
patterns were observed and reflected the way in which isolates had been 
selected. First, if a participant carried an azithromycinR S. aureus at day 
0 or day 3 (representing early/pre-intervention acquisition), the same 
clone was identified at day 28, suggesting that it had been maintained 
regardless of ST or the mac-rolide resistance gene identified during the 4 
weeks post-intervention. This pattern was observed in all nine participants 
in groups 1 and 2 (Figure 3). Second, if a participant acquired an 
azithromycinR S. aureus after day 3 (representing delayed acquisi-tion), 
then the first azithromycinR clone acquired was an ST5 MSSA harbouring 
msr(A). This pattern was observed in seven of the eight participants in 
groups 3 and 4 (Figure 3). Further, this was also observed in the two 
mothers from groups 1 and 2 in which an azithromycinS S. aureus was 
recovered at day 0 (pre-intervention) and an azithromycinR S. aureus at 
day 3 (Figure 3, P593/6 and P592/ 5). In two participants, it appeared that 
the azithromycinR ST5 iso-late recovered at day 6 was replaced by either 
an azithromycinS ST5 (P361/2) or an azithromycinS ST15 (P263/1) isolate 
at day 14, which then switched back to the azithromycinR ST5 isolate at 
day 28 (Figure 3). This could represent repeated clonal replacement in 
these participants, dual carriage of both clones (which would be missed 
by this study as only a single colony was sequenced from each sample) 
or, in the case of P361/2, in vitro plasmid loss. It is also unclear why the 
four participants in group 3 only carry azithromycinS ST15 MSSA prior to 
acquiring azithromycinR MSSA, whereas group 4 are more varied (Figure 
3). Again, this is possibly due to the small sample size considered in this 
study or may reflect an unknown selection pres-sure promoting short-term 
carriage of the azithromycinS ST15 clone in participants assigned to the 
azithromycin treatment arm. 
 
Collectively these isolate timelines suggest that participants who 
received the azithromycin intervention either maintained the 
azithromycinR MSSA, which they probably carried prior to the inter-
vention, or acquired one, replacing an azithromycinS ST15 MSSA, with 
the resulting azithromycinR MSSA being of varied ST and carry-ing either 
msr(A) or erm(C). In participants who received the pla-cebo, only 
azithromycinR ST5 MSSA was acquired, replacing various azithromycinS 
MSSA populations. There are multiple potential explanations for this 
finding. The increased use of azithromycin may have significantly altered 




We have used comprehensive genomic analyses to reveal the dy-
namics of azithromycinR S. aureus colonization in mothers and 
babies after azithromycin treatment or placebo. Plasmid-encoded 
msr(A) in ST5 MSSA was the most common clone, being respon-sible 
for most azithromycinR S. aureus acquisitions in both study arms. 
These results provide critical information to inform a greater 
understanding of the ecological impact of azithromycin prophy-laxis 
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Supplementary Materials and Methods 
 
PregnAnZI trial 
The PregnAnZI trial recruited women delivering at the Bundung Maternal and Child Health 
Hospital (BMCHH) formerly called Jammeh Foundation for Peace (JFP), a government-run 
health facility located in Western Gambia that manages on average 4,500 deliveries per year. 
The population of the catchment area of (BMCHH) includes the main ethnic groups in The 
Gambia and the illiteracy rate is high. Details of the study protocol have been described 
elsewhere [1]. In brief, it was a phase-III, double-blind, placebo-controlled trial where 829 
pregnant women attending the labour ward in the study health facility were randomized to 
receive a single oral dose of 2g of either oral AZI or a placebo (ratio 1:1). Recruitment of trial 
participants started in April 2013 and lasted 12 months, with an additional 2 months of follow-
up.  Study participants were monitored during eight weeks following the intervention and 
nasopharyngeal swabs (NPS) where collected during the first 4 weeks of the follow-up (day 0 
for mothers, and day 3, 6, 14, and 28 for mothers and babies). Other biological samples were 
also collected during the follow-up period but were not considered for this genomic study [2]. 
All study mothers had signed consent during their pre-natal visits before being enrolled into 
the trial. The trial was approved by the Joint MRC/Gambia Government Ethics Committee.  
 
Sample selection  
In order to explore the potential genetic diversity amongst AZIR S. aureus recovered during 
the trial, we stratified isolates collected at day 3 and day 28 into four groups (Figure 1). Two 
groups represented samples from participants assigned to the AZI treatment arm where an 
AZIR S. aureus was recovered at both time points (Group 1) or only at day 28, with an AZI 
susceptible (AZIS) S. aureus identified at day 3 (Group 3). The other two groups represented 
the same microbiological division but for samples recovered from participants assigned to the 
placebo arm (AZIR S. aureus at day 3 and day 28 [Group2], or AZIS S. aureus at day 3 and AZIR 
S. aureus at day 28 [Group 4]). A total of 17 participants (34 isolates) were selected from these 
four groups for this genomic study. To further explore the population dynamics of AZIR 
S. aureus carriage over the follow-up period, all S. aureus recovered from the above subjects 




at other time points (days 0, 6 and 14) were also included. Further detail about isolate 
selection is provided in Figure 1. 
Whole Genome Sequencing  
Genomic DNA was extracted using the GenEluteTM Bacterial Genomic DNA Kit (Sigma). DNA 
libraries were prepared using the Nextera XT kit (Illumina) and sequenced on the NextSeq 500 
(Illumina) using 2 × 150-bp chemistry. One isolate (S80062MN28) was subjected to long-read 
sequencing on the RS-II (Pacific Biosciences) using P6-C4 chemistry. All sequence data 
generated for this study has been made publicly available through the European Nucleotide 
Archive, project accession PRJEB31151. 
 
Bioinformatic Analysis 
Short-read sequence data was assembled using SPAdes v3.11.1 [3], and contigs having a 
coverage less than 5 were excluded as contaminants. Isolate S80062MN28 was assembled 
from both long and short read sequence with Unicycler v0.4.6 in “bold” mode [4]. Annotation 
of plasmid pS80062MN28 was performed using Prokka v1.13.3[5], using plasmid pJSA01 
(accession AP014922.1) [6]. Comparative alignment of plasmid sequences was performed 
using the Artemis Comparison Tool v17.0.1, excluding matches ≤ 100 bp in length[7]. In silico 
MLST and antibiotic resistance gene detection was performed on draft assemblies and 
complete genomes using mlst v2.10 (https://github.com/tseemann/mlst) and abricate 
v0.8.10 (https://github.com/tseemann/abricate), using the NCBI antimicrobial resistance 
database (retrieved 20-Sept-2018) and the virulence factor database (retrieved 14-Aug-
2018).  
 
For the phylogenetic analysis, short-read sequence data was aligned to the complete 
genomes of six S. aureus reference genomes (genome accessions: CP026964.1 [ST1]; 
CP026968.1 [ST5]; CP012970.1 [ST8]; LS483319.1 [ST15]; CP024998.1 [ST152]; LS483314.1 
[ST669]), each selected for being the most closely related complete genome for each ST 
identified in the study population. Variant calling was achieved using Snippy v4.3.5 
(https://github.com/tseemann/snippy). Whole genome alignments were used to construct 
maximum likelihood (ML) phylogenetic trees with IQtree v1.6.5 [8]. Model selection was 
used to find the best nucleotide substitution model for each alignment (chosen according to 
the Bayesian Information Criterion): this was either the HKY+F for ST5 and ST15 [9], or the 
F81+F 




for ST1, ST8, ST152 and ST669 [10]. Alignments composed of greater than 5 isolates (ST5 and 
ST15) were subjected to 1000 ultra-fast bootstrap replicates [11]. ML trees were visualized 
using FigTree v1.4.3 (http://tree.bio.ed.ac.uk/software/figtree/). Core pairwise SNP distances 
were calculated using an in-house pearl script. 
 
The global S. aureus phylogeny was constructed using publicly available genomes and 
metadata as described in Guerillot et al [12]. The 66 isolates sequenced as part of this study 
were added, together with 28 newly sequenced S. aureus genomes from Africa (downloaded 
from the Staphopia database[13]. The 7191 genomes were mapped to the fully assembled 
reference genome S. aureus NRS384 and core genome alignment of the global collection 
(n=7192), all CC5 isolates (n=2735) or all CC15 isolates (n=179) were generated with snippy 
v4.3.6. Maximum likelihood phylogenetic trees were inferred with FastTree v2.1.8 using the 
generalized time-reversible (GTR) model. Trees were plotted and annotated using the R 
library ggtree[14]. Sub-trees of CC5 and CC15 were generated from the full CC5 or CC15 
phylogenetic trees by extracting only isolates with a tip distance of < 23 nodes from the 
isolates sequenced in this study.  
 
Detection of mutations in ribosomal proteins (rplD, rplV, and 23S rRNA) were performed using 
Snippy v4.3.8. Because of the multi-copy nature of the 23S rRNA, mutations were assessed by 
mapping short-read sequence data to a single copy of the gene from CP026968.1 [ST5] and 
calling mutations at a minimum mapped-base frequency of 0.5 (option “--min-frac 0.5”). 
Mutations were not called at a lower frequency as it was expected that they would need to 
be present in the majority of 23S rRNA copies to impact of phenotypic resistance[15, 16]. 
 
Cloning and transformation of ermC and msr(A) genes  
Vector pRAB11 was initially amplified using primers pRAB11_F and pRAB11_R to create a 
backbone for SLiCE (seamless ligation cloning extract) cloning (all primer sequences are 
provided in Supplementary Dataset 2)[17]. The ermC and msr(A) genes were then amplified 
using primers ermC_pRAB11_F and ermC_pRAB11_R, and msr(A)_Saur_pRAB_F and 
msr(A)_Saur_pRAB_R, respectively. The PCR fragments were ligated using SLiCE and 
transformed into IM08B competent E. coli cells[18] .  The transformed cells were plated on 
Luria broth (LB) agar with 100µg/ml ampicillin and incubated overnight at 37ºC.  Successful 




transformation was confirmed by colony PCR.  The confirmed colonies were cultured 
overnight in LB with 100µg/ml ampicillin and plasmids extracted using QIAGEN mini prep kit.  
The empty vector or those containing ermC or msr(A) were electroporated into an ST5 A ZIS 
S. aureus strain (S70065MN00) and plated on LB agar with 10µg/ml chloramphenicol before 
incubating overnight.  Colonies were screen to confirm the presence of either ermC or msr(A) 
genes using the above primers. Antimicrobial susceptibility was tested as outlined below. 
 
Bacterial conjugation 
The donor (S80062MN28; azithromycin MIC 192 μg/ml, rifampicin  MIC <1 μg/ml; fusidic acid 
MIC <1 μg/ml) and recipient strain that was induced to high level rifampicin and fusidic acid 
resistance through serial passage (S70065MN00, azithromycin MIC 1 μg/ml, rifampicin MIC 
>32 μg/ml; fusidic acid MIC >32 μg/ml) were mixed on a membrane filter (Millipore) with a 
donor-to-recipient ratio of 1:1. Plates were incubated overnight at 37°C. The bacterial cells 
were resuspended in PBS and spread on BHI agar plates containing the appropriate 
antibiotics. To quantify conjugative transfer efficiencies, dilutions were plated on BHI media 
containing antibiotics for the selection of; donor cells, recipient cells and plasmid containing 
recipient cells. Transconjugants were selected on plates containing azithromycin, rifampicin 
and fusidic acid all at 32 μg/ml. All conjugation assays were performed in duplicate. Control 
conjugation experiments were performed with the donor strain only, and no spontaneous 
resistant colonies were observed. The resistance profile of donor, recipient and 
transconjugant are summarised in Table S1. 
 
Antimicrobial susceptibility testing 
Phenotypic susceptibility to AZI and erythromycin was determined using Etest (BioMérieux), 
performed as per the manufacturer’s recommendations. Etest values < 4µg/ml were 
interpreted as sensitive , ≥ 8 μg/ml as resistant, and ≥ 4 μg/ml but < 8 μg/ml as intermediate,  
as per the CLSI guidelines [19].   
   
Statistics  
Fisher’s exact test was used to compare the prevalence of sequence types or macrolide 
resistance genes between the azithromycin and placebo group.   A p value of 0.05 was used  
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Table S1. Resistance profile of strains used in conjugation experiments 




Fusidic acid MIC 
μg/ml 
Donor (S80062MN28) 192 <1 <1 
Recipient# 1 >32 >32 
Transconjugants >32 >32 >32 
#Note. Strain S70065MN00 induced to high level rifampicin and fusidic acid resistance 
through serial passage. 
 
 
Figure S1. Phenotypic tests confirming that the acquisition of ermC_2, ermC_13 or msr(A) into 
a susceptible ST5 MSSA (representative of The Gambian lineage identified in this study) 
results in a significant increase in the minimum inhibitory concentration (MIC) to 
azithromycin. 
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6.3 ABSTRACT  
6.3.1 Background:   
Several strategies using azithromycin prophylaxis proved effective in reducing maternal and 
neonatal morbidity/mortality.  However, these interventions are associated with the 
emergence of azithromycin resistant bacterial species.    
We conducted a phase III, double-blind, placebo-controlled randomized trial to determine the 
impact of one 2g oral dose of intrapartum azithromycin on bacterial colonization of Gambian 
women and their babies. In this post hoc analysis, we assess the impact of the intervention 
on macrolide resistance genes, specifically msr(A) and ermC, in the nasopharynx of study 
infants. 
 
6.3.2 Methods:  
Nasopharyngeal swabs (NPS) were collected at birth, 28 days and 12 months.  Genomic DNA 
was extracted from the NPS.  PCRs were performed using primers designed to detect msr(A) 
and ermC.  Products were analysed using QIAxcel advanced Screen gel 1.5.0. 
 
6.3.3 Results:  
The analysis included 936 NPS samples from 312 children.  At birth, the prevalence of msr(A) 
was similar in both arms, increased  in the azithromycin arm at day 28 (60.7% vs. 29.9% in the 
azithromycin and placebo arms, respectively; OR, 3.61 [95% CI, 2.20-5.93]),  and again similar 
between arms at 12 months.  Prevalence of ermC followed a similar pattern, with differences 
between arms only apparent at day 28 (63.9% vs. 45.9% in the azithromycin and placebo 
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arms, respectively; OR, 2.09 [95% CI, 1.29-3.37]).  At day 28, presence of one resistance gene 
was associated with presence of the other resistance gene. 
 
6.3.4 Conclusions:  
Children exposed to azithromycin during labour have a short-term increased prevalence of 
macrolide resistance genes in the nasopharynx which could potentially lead to the spread of 
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6.4 INTRODUCTION 
For decades, oral azithromycin has been used for trachoma elimination (1,2).  More recently, 
prophylactic use of azithromycin has been investigated in low and middle income countries 
as an intervention to decrease infant mortality (3).  Azithromycin given during pregnancy 
increases birth weight (4) and reduces preterm delivery (5); intrapartum azithromycin reduces 
maternal and neonatal infections (6), colonization of Gram-positive bacteria (7) and 
malnutrition at 12 months of age (8). 
However, azithromycin interventions may increase the prevalence of macrolide-resistant 
bacterial species, even after the administration of a single dose (7).  In The Gambia, three 
annual rounds of mass drug administration (MDA) with azithromycin were associated with a 
short and long-term (30 months) increase in both the prevalence of azithromycin-resistant 
and inducible macrolide lincosamides and streptogramin B (MLSB) resistant S. aureus (9).  In 
Papua New Guinea, the proportion of azithromycin resistant S. aureus was five-fold higher 
among pregnant women who received azithromycin compared to a control group (10). 
In our double-blinded placebo-controlled trial conducted in The Gambia (namely PregnAnZI 
trial), a single dose of oral azithromycin was administered during labour to assess the impact 
on bacterial colonization of Gram-positive bacterial species (Staphylococcus aureus, 
Streptococcus pneumoniae and group B Streptococcus) in both mothers and their offspring.  
The intervention significantly reduced bacterial colonization but increased the prevalence of 
azithromycin resistant S. aureus during the neonatal period.  By day 28, prevalence of S. 
aureus azithromycin resistance was significantly higher in the intervention compared to 
placebo arm (16.7%vs 4.5%; P < .001) (7).  The observed increase was probably the result of 
the high concentration of azithromycin in the breast-milk (11). The carriage of azithromycin 
resistant S. aureus strains waned by the age of 12 months (12). 
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Although, macrolide resistance is known to result from both gene acquisition or mutation 
including efflux genes (mef(A), msr(D), msr(A/B) and methylation genes (ermA, ermB and 
ermC), molecular analysis of the azithromycin resistant S. aureus strains isolated in the 
PregnAnZI trial from both mothers and babies in The Gambia revealed that the genetic 
determinants responsible for macrolide resistance were predominantly, if not exclusively, 
msr(A) and ermC  in this population(13).  Both msr(A) and ermC genes are carried by mobile 
genetic elements, hence horizontal spread between bacteria colonising the same ecological 
niche can take place through transformation, conjugation or transduction (14–16).  A 
comprehensive genomic analysis was performed on S. aureus as the bacterium was found to 
have high rates of macrolide resistance among women given azithromycin and their children, 
and hence may play a greater role in transmission of macrolide resistance genes.  In fact, 
msr(A) and ermC can also be found in other bacteria that colonises the nasopharynx such as 
Staphylococcus, Bacillus subtilis, Streptococcus, Enterococcus, Corynebacterium and 
Pseudomonas species (17–21). Subsequently, screening a single bacterium (i.e. S. aureus) 
isolated from a sample to determine prevalence of resistance following oral azithromycin 
interventions may underestimate the true prevalence.  Macrolide resistance needs to be 
more accurately assessed by examining the prevalence of these two genes across all bacterial 
species in a large number of clinical samples. The aim of this post hoc study is to evaluate the 
effect of intrapartum azithromycin on the prevalence and relative fluorescence of the 
macrolide resistance genes (i.e. msr(A) and ermC) in the nasopharynx at different time points 
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6.5 MATERIALS AND METHODS 
6.5.1 PregnAnZI trial and subsequent cross-sectional study (CSS) 
The PregnAnZI trial was a phase-III, double-blind, placebo-controlled trial in which 829 
pregnant women attending the labour ward were randomized to receive either a single oral 
dose (2g) of intrapartum azithromycin or placebo (ratio 1:1).  The study protocol has been 
described elsewhere (22). Participants were recruited between April 2013 and April 2014. NPS 
were collected from babies at different time points during the neonatal period.  In addition, 
NPS were collected in a follow up survey done when the children were between 11 and 13 
months of age. 
 
6.5.2 Sample selection for this post hoc study 
Only children with NPS collected at birth (day 0), day 28 and at 12 months were eligible for 
inclusion in this post hoc study.  A random sample of 312 children with the three samples (155 
from the azithromycin and 157 from the placebo arm) were included in the current study, 
making a total of 936 samples (Figure 1).  
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6.5.3 Sample collection and storage 
NPS samples were collected by passing the tip of a calcium alginate swabs across the mucosa 
of the posterior wall of the nasopharynx and immediately inoculated into vials containing 
skim milk-tryptone-glucose-glycerol (STGG) transport medium (22).  The vials were then sent 
to the laboratory for storage within 8 hours at -70C. 
 
6.5.4 Ethical Approval 
Both the main trial and the 12month survey were approved by the Joint Gambia 
Government/MRC Ethics Committee.  Mothers of study children signed an informed consent 
for the trial and another one for the 12 months survey. 
 
6.5.5 Laboratory method   
6.5.5.1 DNA extraction 
Genomic DNA was extracted directly from NPS using QIAamp DNA Mini Kit (QIAGEN, United 
Kingdom) protocol with some modifications.  Frozen nasopharyngeal swabs in STGG medium 
were initially thawed at room temperature, vortexed briefly and 200μL of the sample added 
to 200μL of lysis buffer (TE buffer, lysozyme 30mg/ml, mutanolysin 50U/ml, lysostaphin 
200μg/ml) before being incubated at 37°C for 1 hour.  The manufacturer’s protocol was 
followed for remainder of the extraction. The DNA was eluted in 100µl volume and stored at 
-20°C.  
 
105 | P a g e  
 
6.5.5.2 PCR   
The primers for the amplification of the macrolide resistance genes [msr(A)_F 
ATCCAATCATTGCACAAAATCTAACATT, msr(A)_R TAAATAGCTTCAAGTAAAGTTGTCTTACC and 
ermC_F CTTGTTGATCACGATAATTTCCAAG, ermC_R TTGTATTCTTTGTTAACCCATTTCATAAC] 
were designed using Primer 3 and synthesized by Metabion, Germany.  Primer sets were 
diluted to a final concentration of 10μM and assayed in 20μL PCR reaction volume containing 
1µL of each primer, 10μL 2x Phire Green Hot Start II PCR (Thermo Scientific, United Kingdom) 
reaction buffer, 7μL nuclease water and 1µL of the genomic DNA.  The cycling conditions 
included an initial denaturation at 98°C for 30 seconds, 35 cycles of denaturation at 98°C for 
5 seconds, annealing at 52°C for 5 seconds and extension at 72°C for 10 seconds with a final 
extension at 72°C for 1 minute. Fully sequenced S. aureus carrying either the ermC or msr(A) 
genes were used as positive controls. 
 
6.5.5.3 Electrophoresis  
PCRs were performed alongside DNA extract from a pure S. aureus isolate known to carry 
either the ermC or msr(A) gene (positive controls) (13).  The PCR products were analysed using 
QIAxcel advanced Screen gel 1.5.0 (QIAGEN, UK) (23) with a tolerance rate of ±15% of the 
expected band size (msr(A) 145bp and ermC 398bp).  Results were categorized as negative or 
positive for macrolide resistance gene prevalence.  In all the PCR reactions, the relative 
fluorescence unit (RFU) signal for the positive controls was greater than 1RFU as each S. 
aureus control was prepared from a pure laboratory culture and contained a high quantity of 
the PCR gene targets.  Based on the above, amongst samples positive for msr(A) or ermC, an 
aleatory cut off   was determined as low (≤1.00 RFU) or high (>1.00 RFU); used as a qualitative 
measurement to estimate the burden of macrolide-resistance bacteria in the sample. 
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6.5.5.4 Statistics  
Pearson’s χ2 test was used to compare the prevalence and relative fluorescence of macrolide 
resistance genes between arms at birth, day 28 and at 12 months.  The χ2 test was also used 
to test for an association between the resistance genes at day 28.  This analysis was stratified 
by trial arm, and a test for interaction was done to test whether the strength of association 
varied between arms.  P-value ≤ 0.05 was used as the cut off for statistical significance.  All 
analyses were carried out using Stata version 12.1 software. 
 
6.6 RESULTS  
6.6.1 Study population and samples 
Baseline characteristics of the 312 study infants and their mothers selected for this post hoc 
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Table 1. Baseline characteristics of study mothers and babies  
  
Characteristics  Azithromycin n= 155  Placebo n= 157 p value  
Mother information        
Maternal age(years) at delivery, mean (SD) 26.7(5.4)a   26.9(5.0)   
Fundal height(cm), mean (SD)b 35.8(2.6)  35.8(3.3)    
Mode of delivery       
 Vaginal 155(100) 157(100)   
 Caesarean 0 0   
Ethnicity     0.405 
 Mandinka 68(43.9) 68(43.3)   
 Jola 30(19.4) 26(16.6)   
 Wollof 21(13.6) 14(8.9)   
 Fula 18(11.6) 27(17.2)   
    Sarahule  7(4.5) 5(3.2)   
 Others 11(7.1) 17(10.8)   
Season of birthc       
    Dry  114(73.6) 118(75.2) 0.745 
    Wet  41(26.5) 39(24.8)   
Child information at birth up to day 28       




   9 – 10  142(92.2) 147(93.6)  
   7 - 8  12(7.8) 9(5.7)  
   ≤6 0 1(0.7)  
Twins 1(0.7) 4(2.6) 0.181 
Singleton  154(99.3) 153(97.4)  
Sexe       
 Female 83(53.9) 73(47.4) 0.254 
 Male 71(46.1) 81(52.6)   
 
Data are presented as No. (%) unless otherwise indicated. 
Abbreviation: SD, standard deviation. 
aone missing data item in the azithromycin arm. 
b6 missing data (2 in the azithromycin arm and 4 in the placebo arm). 
cwet season = June to October, dry season = November to May  
d1 missing data in the azithromycin arm 
e4 missing data (1 in azithromycin and 3 in placebo arm) 
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6.6.2 Prevalence of macrolide resistance (msr(A) and ermC) genes  
Prevalence of msr(A) gene in infant NPS at birth was similar between trial arms (25.2% vs. 
25.5% in the azithromycin and placebo arms, respectively).  At day 28, prevalence of msr(A) 
gene was higher among children in the azithromycin arm (60.7% vs. 29.9%; OR, 3.61 [95% CI, 
2.20-5.93]) but differences between arms waned by the age of 12 months (17.4% vs. 18.5% 
in the azithromycin and placebo arms, respectively; OR, 0.93 [95% CI, 0.50-1.73]). See Table 
2 & Figure 2a.   
Prevalence of ermC gene in the infant NPS at birth was also similar between trial arms (30% 
vs. 35.0% in the azithromycin and placebo arms, respectively).  At day 28, prevalence of ermC 
gene was higher among children in the azithromycin arm (63.9% vs. 45.9%; OR, 2.09 [95% CI, 
1.29-3.37]) and again differences between arms waned by the age of 12 months (51.6% vs. 
43.3% in the azithromycin and placebo arms, respectively; OR, 1.4 [95% CI, 0.87-2.24]). See 
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Table 2. Prevalence of msr(A) and ermC genes by Arm 
 
Day 0 Day 28 Year 1 
AZI (%) P’bo (%) OR (95% CI) p 
value 
AZI (%) P’bo (%) OR (95% CI) p 
value 
AZI (%) P’bo (%) OR (95% CI) p 
value 
Gene n = 155  n = 157 
  
n = 155  n = 157 
  
n = 155  n = 157 
  
msr(A)             
yes 39(25.2) 40(25.5)     94(60.7) 47(29.9)     27(17.4) 29(18.5)     
no 116(74.8) 117(74.5) 0.98(0.57-1.69) 0.949 61(39.3) 110(70.1) 3.61(2.20-5.93) <0.001 128(82.6) 128(81.5) 0.93(0.50-1.73) 0.809 
ermC             
yes 47(30.3) 55(35.0)     99(63.9) 72(45.9)     80(51.6) 68(43.3)     
no 108(69.7) 102(65.0) 0.81(0.49-1.33) 0.375 56(36.1) 85(54.1) 2.09(1.29-3.37) 0.001  75(48.4) 89(56.7) 1.40(0.87-2.24) 0.142 
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6.6.3 Relative fluorescence of macrolide resistance genes 
Samples with high relative fluorescence of msr(A) were only found at day 28.  At that time 
point, the prevalence of high fluorescence signals was higher in samples from children in 
the azithromycin arm [15.5% vs. 0.6% among infants in the azithromycin and placebo arms 
respectively, OR 28.6 95% CI, 4.50-1182.43]) (Figure 3a).  Similarly, high relative 
fluorescence for ermC gene was observed at day 28 with higher prevalence among children 
in the azithromycin arm (10.3% vs. 0.6% in the azithromycin compared to placebo arm, OR 
18.0 95% CI 2.70-757.60) (Figure 3b). 
 





113 | P a g e  
 
6.6.4 Association of msr(A) and ermC genes at day 28 
At day 28, there was a positive association between ermC and msr(A) genes (OR 2.31 95%CI 
1.42-3.76) Table 3. Although the association appeared to be stronger in samples from the 
placebo arm, there was no evidence of an interaction by study arm (p=0.162). 
 













                                 ermC                              
 
OR 95% CI p-value 
Both arms Pos n(%)  Neg n(%)    
msr(A)      
Pos  93(54.4) 48(34.0)    
Neg  78(45.6) 93(66.0) 2.31 1.42-3.76 <0.001 
Azithromycin Arm      
msr(A)   
   
Pos 63(63.6) 31(55.4) 
   
Neg 36(36.6) 25(44.6) 1.41 0.68-2.90 0.311 
Placebo Arm  
    
msr(A) 
  
   
Pos 30(41.7) 17(20.0) 
   
Neg 42(58.3) 68(80.0) 2.86 1.33-6.20 0.003 
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6.7 DISCUSSION 
Our analysis shows that intrapartum azithromycin resulted in a short-term increased 
prevalence of both carriage and relative fluorescence of macrolide resistance genes (msr(A) 
and ermC) in the nasopharynx of study children.  One year later, such difference had waned.  
The increased detection of the msr(A) and ermC genes at day 28 among children whose 
mothers received intrapartum azithromycin mirrors the reported phenotypic resistance for 
S. aureus at the same time point (7) that subsequently disappeared, also, by 12 months 
(12). 
Our previous genomic analysis identified msr(A) as the dominant macrolide resistance gene 
in a sub-set of children carrying azithromycin-resistant S. aureus during the neonatal 
period, followed by ermC (13).  Both msr(A) and ermC genes were present at all three time 
points in both arms.  However, at day 28, the prevalence of macrolide resistance gene and 
relative fluorescence was highest among children whose mothers received intrapartum 
azithromycin for both msr(A) and ermC compared to children whose mothers received 
placebo.  This finding suggested that exposure to azithromycin contributes to an increase 
in macrolide resistance gene carriage but also an increase in bacterial or resistance gene 
load.  
Data on msr(A) gene prevalence following prophylactic azithromycin are scarce.  In 
Australia and New Zealand, a non-significant increase in carriage of msr(A)  was observed 
in patients with non-cystic fibrosis bronchiectasis on long-term (48 weeks) erythromycin (a 
sister macrolide to azithromycin) (24). However, in Niger children under 5 who received 
twice-a-year azithromycin had approximately,  30% higher prevalence of the streptococcal 
macrolide resistance determinant mefA/E, an equivalent of the staphylococcal msr(A) 
gene, than did children in the once-a-year group (25). Although formal comparisons 
between the aforementioned trial and our trial is difficult because of the different designs 
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(community seasonal prophylaxis versus single-dose intrapartum administration), it 
appears that mefA/E persisted longer within the population than msr(A) or ermC.  We did 
not include mefA/E in our study as the gene is predominantly associated with Streptococci, 
and in our trial azithromycin resistance following intrapartum oral intervention was only 
significantly increased for Staphylococcus and not  Streptococcus (7,12).  
The increase in ermC prevalence observed at day 28 may be associated with increased  
macrolide resistance  in the study population, including resistance to clindamycin and 
streptogramin B depending on whether the presence of the gene results in an inducible or 
constitutive phenotype (26,27).  All S. aureus isolates carrying ermC from our previous 
molecular and phenotypic analysis showed constitutive resistance (12).  Unlike msr(A) 
gene, the prevalence of ermC at 12 months was non-significantly higher in the azithromycin 
arm than in the placebo arm. Additional studies should determine whether the ermC gene, 
beyond being as prevalent as msr(A), is also more persistent. 
In our previous molecular analysis, we observed a negative association between the 
resistance genes whereby S. aureus isolates were positive for either msr(A) or ermC (13).  
The current analysis identified a positive association between the two genes.  Taken 
together, these results indicate that in a given sample it is common for both macrolide 
resistance genes to be present but are likely carried by different bacterial isolates or 
species.  For example S. epidermidis and S. arlettea are known to carry ermC and msr(A) 
respectively (20,21).  
We also observed discrepancies between the current genotyping analysis and the former 
phenotyping in the prevalence of resistance.  Most striking, the phenotypic prevalence of 
S. aureus resistance at day 0 was <1% compared to our 25%-35% for genotypic prevalence 
(7).  It is important to note that these percentages are not comparable because phenotypic 
prevalence was estimated from cultured isolates of S. aureus, whereas genotypic 
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prevalence was estimated from detection of the macrolide resistance genes, irrespective 
of the bacterial species harbouring it. In fact, our findings suggest that most msr(A) and 
ermC genes found in the nose are carried by non S. aureus species and potential serve as a 
reservoir for macrolide resistance genes, underlying the importance of genotypic analysis 
of sample rather than individual bacteria to complement the more standard phenotypic 
methods. 
Our study had some limitations. First, approximately half of the children that took part in 
the main trial were included in this study, although a significant selection bias is unlikely as 
most of the excluded children were beyond the upper age limit for inclusion. Second, only 
three time points were considered in this analysis, and therefore it is not possible to 
determine the length of time beyond 28 days in which the high prevalence of resistance in 
the azithromycin arm was maintained. Third, we did not use a housekeeping gene or 
control for the quality of DNA during the extraction.  We do not consider that this has 
greatly affected the overall result as consistent methodology was applied to all samples in 
terms of collection, extraction of DNA and molecular testing.  Fourth, the DNA 
concentration was not normalised prior to molecular testing.  Therefore, we have 
interpreted the RFU values as suggestive of a difference in bacterial or gene load in the 
samples.  Further, we only compared the relative fluorescence of the same gene between 
samples as the primers may have different amplification efficiency, as previously done by 
Keenan J D. et al  (25).  In addition, the clinical significance of detecting a macrolide 
resistance gene from an NPS for clinical care, in the absence of knowing whether the gene 
is carried by a pathogenic or commensal species, is not known.  Finally, it was not possible 
to ascertain from the PCR used to detect msr(A) and ermC whether the genes were 
functional. 
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6.8 CONCLUSION 
Children whose mothers were exposed to azithromycin during labour had increased 
prevalence and higher relative fluorescence of macrolide resistance genes (msr(A) and 
ermC) during the neonatal period but not at 12 months of age.  Such results indicate a 
potential risk of antibiotic resistance genes spreading within the population during the 
neonatal period and highlights the importance of macrolide resistance genes surveillance 
in the event that prophylactic azithromycin interventions are rolled out. 
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7.1 GENERAL DISCUSSION  
A proof-of-concept trial (namely PregnAnZI-1) showed that intrapartum oral azithromycin 
prophylaxis significantly reduced maternal and neonatal colonisation of Gram-positive 
bacteria and clinical infections [56, 140].  Consequently, the intervention is currently being 
evaluated in larger trials to assess efficacy in maternal and neonatal sepsis as well as 
neonatal mortality.  However, efficacy results will need to be balanced with the effect of 
the intervention on antimicrobial resistance.  Therefore, the future consideration of 
intrapartum oral azithromycin as a public health intervention will need a clear 
understanding of the impact on bacterial carriage and antimicrobial resistance.   
In The Gambia, S. aureus is the main cause of bacteraemia in all age groups and the most 
prevalent cause of neonatal sepsis [11, 30, 31]. The bacterium has the potential to develop 
resistance to many antibiotics including macrolides following exposure.  Intrapartum oral 
azithromycin prophylaxis has also been shown to result in increased prevalence of 
azithromycin resistance S. aureus shortly following exposure [56].  These investigations 
conducted as part of my PhD are important for future decisions on the use of oral 
azithromycin in labour to reduce maternal and neonatal mortality in the Gambia and 
beyond. 
I have shown that although azithromycin resistant S. aureus increased significantly shortly 
following exposure among both mothers and their new-borns, the resistance waned by 12 
months. At this time point, no differences were observed in the prevalence of carriage and 
antibiotic resistant bacteria between children whose mothers were exposed to 
azithromycin during labour compared to those children whose mothers had taken placebo 
[154].  Similarly, no differences were found between study arms in the prevalence of S. 
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aureus resistance to other antibiotics such as erythromycin, clindamycin, chloramphenicol, 
cefoxitin and cotrimoxazole.  This is an important result as the above antibiotics are 
commonly used in The Gambia for the treatment of diseases cause by S. aureus.  
The finding suggests that the intervention has no risk of azithromycin or other antibiotic 
resistant S. aureus strains persisting in the nasopharynx of study children following 
exposure.  However, given an impact on resistance was observed in the short term, 
following the rollout of oral azithromycin prophylaxis to all pregnant women in labour, 
continuous monitoring will be required among exposed individuals but also their close 
contacts for the emergence of antibiotic resistance.  This will be necessary as following the 
roll out, a large number of women and babies will be exposed to the antibiotic resulting in 
high antibiotic pressure within the communities.  This may result in the emergence of 
macrolide resistance in bacterial species not observed during the trial.  In the trial, the 
antibiotic pressure was low since only a small proportion of the pregnant women and their 
babies in the population were exposed to the antibiotic. 
Understanding the genetic basis of S. aureus macrolide resistance is also very important as 
it permits a more detailed understanding of the impact of azithromycin exposure at the 
molecular level.  It sheds light on the different macrolide resistance mechanisms used by 
bacteria.  It also provides genetic information about the genes responsible for resistance 
and whether they are chromosomal or located on a mobile genetic element, which may 
have implications for the risk of dissemination of resistance in the population.  Antibiotic 
resistance genes located on a mobile genetic element have the potential to transfer 
horizontally between bacteria of the same or different species colonising the same 
ecological niche.  Hence, screening one colony grown from a sample to determine 
prevalence of macrolide resistance following oral azithromycin interventions may 
underestimate the real prevalence of resistance.  
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I have identified the two main genes (msr(A) and ermC) located on mobile genetic elements 
encoding protein products resulting in azithromycin resistance in our population.  The 
msr(A) gene was the dominant gene associated with S. aureus macrolide resistance among 
all isolates recovered from mothers and babies in the study.  All S. aureus isolates in the 
placebo arm carried the msr(A) gene suggesting the dominance of this gene type circulating 
in the population prior to the intervention.  The importance of such finding is that it 
provides information about the mode of transmission and spread within the population as 
chromosomal genes transfer mainly from parent to daughter cells whereas genes located 
on mobile genetic elements are able to transfer horizontally between bacteria of same or 
different species through transformation, conjugation or transduction [155, 156].  
Intrapartum oral azithromycin intervention appeared to select for the ermC gene as 36% of 
resistant S. aureus isolates from mothers and babies exposed to antibiotic carried the gene 
as opposed to 0% in the placebo arm.  The selection of one gene type over the other does 
not appear to have any negative consequences as there was no evidence of induced 
macrolide resistance S. aureus associated with the ermC gene.  The significance of the 
above findings is that I have been able to establish the genes predominantly associated 
with macrolide resistance among one of the most important bacterial species causing 
infections in The Gambian population and demonstrate how the prevalence of these genes 
was affected by the intervention. I have also been able to show that although the 
intervention appears to select one resistance gene type over the other, overall, it has no 
negative consequences as the resulting gene types were mainly constitutive indicating 
resistance to macrolide, lincosamides and streptogramin B antibiotics but susceptible to 
other antibiotics. 
Further, I have shown the circulating S. aureus sequence types (STs) examined dominated 
by ST5 and the genetic relatedness of isolates from the same individuals at different time 
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points.  ST5 was dominant among mothers and babies but the intervention appears to 
select for ST15 over ST5 among azithromycin exposed individuals.  Although ST15 is more 
often associated with pathogenicity it is also more susceptible to antibiotic and lacks the 
backbone to carry the mecA gene that confers methicillin resistance [157].  S. aureus 
isolates coming from the same individual at different time points were genetically very 
closely related.  
Previously, I established that both msr(A) and ermC genes were located on a mobile genetic 
element [158] with the potential of resistance genes transferring horizontally between 
bacteria. I then analysed prevalence in nasopharyngeal sample at three time points (at 
birth, day 28 and 12months) among infants from the azithromycin and placebo arms of the 
PregnAnZI-1 study. The PCR method used detected the presence of the genes regardless of 
the bacterial source.  
I found that prevalence of the macrolide resistance genes (msr(A) and ermC) in the 
nasopharynx were significantly higher especially by day 28 among children exposed to intra 
partum azithromycin compared to those in the placebo group.  The prevalence of 
azithromycin resistance genes was about 4 fold higher at day 28  in the nasopharynx of 
children exposed to azithromycin compared to the prevalence of S. aureus azithromycin 
resistance previously reported among the same subjects at the same time point [56]. It is 
important to note that these percentages are not comparable because phenotypic 
prevalence was estimated from cultured isolates of S. aureus, whereas genotypic 
prevalence was estimated from detection of the macrolide resistance genes, irrespective 
of the bacterial species harbouring it.  In fact, our findings suggest that most msr(A) and 
ermC genes found in the nose are carried by non S. aureus species [124, 159-162] and 
potentially serve as a reservoir for macrolide resistance genes, underlying the importance 
of genotypic analysis of sample rather than individual bacteria to complement the more 
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standard phenotypic methods. In addition, molecular detection of antibiotic resistant 
genes directly from samples following azithromycin exposure is considered highly relevant 
for public health as an early “early warning” system compared with the slower expected 
changes in indicator pathogens from clinical samples [163].  Consistently, the relative 
fluorescence of both genes was also higher among children exposed to azithromycin 
compared to those in the placebo group with the peak at day 28 similar to what was 
observed for S. aureus resistance [56]. 
 
7.2 LIMITATIONS  
A number of limitations apply to the above investigations.  In assessing the long-term 
impact of the intervention on carriage and resistance, no samples were collected between 
day 28 of the main trial and the survey done at the infants’ first birthday. Therefore, I was 
unable to determine how long S. aureus resistant isolates persisted in the population. Such 
information is important to determine the potential risk of resistance bacteria transmission 
and establishment within the population. In addition, I didn’t assess if resistant strains are 
transmitted or not to close contacts beyond the mother and baby pair which is also 
important for establishing resistance at the community level.   
For the genomic investigation of S. aureus strains from mothers and babies, the main 
limitation relates to the fact that only a single colony was picked from each nasopharyngeal 
sample.  Individuals may be colonised by more than one S. aureus strain hence the potential 
“cloud of diversity” that may exist within the sample cannot be accounted for when using 
a single colony pick. This limits the interpretation of results in terms of understanding the 
diversity of S. aureus genotypes colonising mothers and babies at the different time points.  
In the PCR detection of staphylococcal macrolide resistance genes, the DNA concentration 
was not normalised prior to molecular testing.  Therefore, I interpreted the RFU values as 
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suggestive of a difference in bacterial or gene load in the samples rather than a quantitative 
measure of the different genes.  The copy numbers of the different genes in the samples 
are bound to affect the signal intensity of the fluorescence. Again, this analysis used 
samples at day 0, 28 and 12 months and therefore there is a big gap between the latest 
two samples.     
 
7.3 CONCLUSIONS  
Emergence of antimicrobial resistant bacteria following intrapartum oral azithromycin 
exposure was of concern.  All of the above findings indicate a short-term increase in the 
prevalence of azithromycin resistant S. aureus that waned 12 months following exposure.  
Further, there was no increase resistance to other commonly used antibiotics.  In The 
Gambia, it is likely the prevalence of antimicrobial resistance will not persist following the 
rollout of intrapartum oral azithromycin prophylaxis to all pregnant women in labour as 
baseline azithromycin resistance in the country is very low.  Although these findings are 
reassuring in a country like The Gambia where baseline azithromycin resistance was low, I 
don’t know how they would translate to other countries with higher baseline resistance 
prevalence.  If the intervention is implemented, continuous monitoring of antibiotic 
resistance will be necessary for S. aureus as well as other potentially pathogenic bacteria. 
 
7.4 FUTURE DIRECTIONS 
It has been established that prevalence of azithromycin resistance S. aureus increased up 
to day 28 but by 12months the resistance waned.  Future studies should collect samples 
monthly from both mothers and babies between day 28 and 12 months post intervention 
in order to more accurately determine the exact time point when resistance disappeared.  
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The transmissibility of azithromycin resistant S. aureus strains that emerged shortly 
following azithromycin prophylaxis especially to close contact within the household should 
also be investigated 
Azithromycin will probably not decrease carriage and may increase resistance to Gram-
negative bacteria.  Currently there are no data on the impact of intrapartum oral 
azithromycin on Gram-negative bacteria (e.g. Escherichia coli, Pseudomonas aeruginosa, 
Klebsiella pneumoniae).  Future studies will need to investigate both the short and long-
term impact of the intervention on the carriage and antibiotic resistance of these bacteria.   
Assessment of antibiotic resistance using phenotypic methods should always be completed 
by molecular testing of antibiotic resistance genes directly from the sample in order to 
obtain a more accurate measure of antibiotic resistance prevalence. 
Following the successful implementation of the intrapartum oral azithromycin, continuous 
surveillance at population level should be conducted for colonisation by performing 
periodical cross-sectional studies of azithromycin resistance.  Further, rates of azithromycin 
resistance bacteria from clinical samples collected from patients admitted at referral 
hospitals countrywide should be investigated. 
Finally, a detailed investigation of the impact of the intervention on nasopharyngeal, skin, 
vaginal, break milk microbiomes of exposed and unexposed individuals using 
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